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Transthyretin (TTR) amyloidosis is a progressive, fatal disease in which deposition of 
amyloid derived from either mutant or wild-type TTR causes severe organ damage and 
dysfunction.  TTR cardiomyopathy is an infiltrative, restrictive cardiomyopathy characterized by 
progressive left and right heart failure.  Familial amyloid cardiomyopathy (FAC) is driven by 
pathogenic point mutations in the TTR gene that destabilize the TTR tetramer, prompting its 
dissociation into dimers and monomers, with subsequent misfolding, aggregation and deposition 
of toxic TTR amyloid aggregates in the myocardium.  The most prevalent mutation that causes 
FAC is the V122I variant, carried by 3.4% of African Americans, that increases the risk of 
cardiomyopathic events several-fold in this population.  AG10, a potent TTR kinetic stabilizer, 
prevents dissociation of V122I-TTR in serum samples obtained from patients with FAC.  
Further, we have described structural, biochemical, and animal studies of AG10 which reveal 
mechanistic and structural insights on the ability of AG10 to mimic the disease suppressing 
T119M variant in stabilizing TTR. 
The second part of the thesis discusses harnessing TTR as a platform to enhance in vivo 
half-life (t1/2) of therapeutic peptides.  Native peptides typically display short in vivo t1/2, 
however conjugation of peptides to macromolecules causes steric hindrance which often harms 
the binding of peptides to target receptors, compromising the in vivo efficacy.  Utilizing 
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Gonadotropin Releasing Hormone (GnRH) as a model peptide, we show that t1/2 may be 
extended without compromising potency.  Our approach involves endowing peptides with a 
small molecule that binds reversibly to the serum protein transthyretin.  Our strategy was 
effective in enhancing the t1/2 of an agonist for GnRH receptor while maintaining its binding 
affinity, which was translated into superior in vivo efficacy.  
The third and final part of the thesis describes our effort on developing a fluorescent 
probe to quantify TTR in human serum using fluorescence polarization.  TTR is used as a marker 
for nutritional and inflammatory status in critical patients.  This assay development has the 
potential to minimize lab cost, effort, and time with regards to determination of TTR 
concentration in patients. 
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Chapter 1: Introduction 
1.1 Transthyretin 
Transthyretin (TTR) or prealbumin is a 56 kD homotetrameric protein present in plasma and 
cerebrospinal fluid (CSF).  The crystal structure image of TTR is shown in Figure 1.1.  TTR is 
synthesized by the liver and secreted into the blood at a concentration of approximately 5 µM, 
where it acts as a backup carrier of thyroxine (T4) (<1% bound) and the primary carrier of holo-
retinol-binding protein (RBP).  TTR is also synthesized by the choroid plexus in the CNS and 
secreted into the CSF at a concentration of approximately 500 nM [1, 2].  
Transthyretin has been shown to be one of more than 30 proteins whose aggregation may 
cause disease by amyloid fibril formation in soft tissue, nervous system, and solid organs due to 
various point mutations which destabilize the tetrameric form of the protein or lack of chaperone 
or degradation activity leading to malformed protein, typically seen in the elderly [3].  
Transthyretin dissociation, misassembly and aggregation are known to be primarily responsible 
for several amyloid-related diseases such as familial amyloid polyneuropathy (FAP), familial 
amyloid cardiomyopathy (FAC) and senile systemic amyloidosis (SSA).  While the V122I 
variant associated with FAC is kinetically destabilized, FAP is predominantly associated with the 
thermodynamically destabilized V30M-TTR variant.  
16 
 
Figure 1.1 Crystal Structure image of Transthyretin. 
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1.2 Expression of TTR 
The plasma TTR is primarily synthesized in the liver while TTR in the brain is synthesized 
by choroid plexus.  TTR is also synthesized at lower amounts in several other tissues like retinal 
pigment epithelium of the eye, in the islets of Langerhans of the pancreas, intestine and 
meninges [4].  
TTR present in blood is produced and secreted by the hepatocytes in the liver and normal 
TTR concentrations in healthy adults range between 0.2 – 0.4 mg/ml (20 – 40 mg/dL or about 
3.5 – 7 µM) [5].  As a consequence, when the liver is participating in acute phase response to 
injury, malnutrition or chronic inflammation, there is a significant decrease in plasma TTR 
levels.  TTR levels are therefore used as a marker for nutritional and inflammatory status in the 
clinic, specifically in patients who display critical health status where it is difficult to obtain a 
more detailed and comprehensive nutritional assessment such as evaluation of albumin, α1-acid 
glycoprotein, and C-reactive protein.  Additionally, due to the short t1/2 of TTR (t1/2 = 2 days), a 
more sensitive assessment of nutritional status can be made in comparison to long-lived proteins 
like albumin (t1/2 = 21 days) [6].  
1.3 Structure of TTR 
Human TTR is a 56 kDa homotetramer composed of four identical 127 amino acid residue 
subunits (~14 kDa) that form an extensive β-sheet structure (Figure 1.1) [7].  The four identical 
subunits (or monomers) of TTR assemble to form an internal channel at the weaker dimer–dimer 
interface which is the site of binding for two T4 molecules [4, 8].  Studies have revealed that due 
to the presence of two other T4 transport proteins in blood these T4 binding sites remain largely 
unoccupied in humans (<1 % T4 bound) and among those occupied, only one site is typically 
filled as there is negative cooperativity in the binding of the second T4 site [9, 10].  In addition to 
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thyroid hormones (T4) and its metabolites, several other pharmacologic agents and natural 
products, such as plant flavonoids, nonsteroidal analgesic drugs, and inotropic bipyridines, are 
strong competitors for T4 binding to TTR and have binding affinities greater than T4 [4, 11]. 
The structure of human wild-type TTR (WT-TTR) was one of the first proteins to be 
determined by X-ray crystallography [2].  Currently, there are about 267 reported TTR crystal 
structures and their variants listed in the Protein Data Bank (PDB, www.rcsb.org) representing 
multiple species of protein (human, rat, mouse, fish, yeast, and bacteria).  Studies have shown 
that the amino acid sequence of human WT- TTR is roughly 85% identical to that from various 
other species,  however the T4 binding site remains highly conserved [12].  The three 
dimensional structures of WT-TTR structure with different ligands (RBP, T4, etc.) are depicted 
in Figure 1.2. Each subunit (monomer) of TTR consists of eight beta strands, denoted A to H, 
and one short alpha helix.  These eight β-strands form two β-sheets, comprised of the strands D-
A-G-H and C-B-E-F, together creating an immunoglobulin-like β-barrel structure.  The two 
monomers dimerize mainly through H-strands forming antiparallel main-chain, main-chain 
interactions and through F-strands forming interactions between side chains and interconnecting 
water molecules.  Then, these dimers interact through hydrophobic interactions between AB and 
GH loops forming a tetramer with a hydrophobic channel between the dimers where T4 binds 
[13].  Each T4 binding site can be divided into three halogen-binding pockets (HBP), namely 
HBP1, HBP2, and HBP3. HBP1 forms the outermost part of the channel, consisting of the side 
chains of Met13, Lys15 and Thr106.  HBP2 forms the middle portion of the channel consisting 
of the side chains of Leu17, Ala109, Leu110, and the hydrophilic main chain carbonyl groups of 
Ala108, and Ala109.  HBP3 forms the last and innermost part of the channel and comprising the 
side chains of Ala108, Ala109, Leu110, Ser117, and Thr119.  The hydrophilic part of HBP3 is 
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formed by the side chains of Ser117 and Thr119, and the main chain carbonyl and amino groups 
of Ala108, Ala109, Leu110, and Thr118. 
1.4 Physiological Function of TTR  
As mentioned earlier, the most studied and acknowledged role of TTR is the transport of T4 
and holo-RBP.  However, recent studies have indicated that TTR may also play an important 
physiological role in proteolysis and transport of other miscellaneous ligands [14]. 
TTR as a transporter.  TTR is not the primary transporter of T4 (less than 1 % bound), due 
to the presence of two other T4 transport proteins in blood, thyroxine-binding globulin (TBG) 
and albumin, the T4 binding sites remain largely unoccupied in humans (Figure 1.2) [15, 16].  
However, in CSF, TTR is the major transporter of T4 in both humans and rats. Interestingly, 
unlike in human plasma, TTR is the major transporter of T4 in rats.  As there is negative 
cooperativity between the two T4 binding pockets, each TTR tetramer carries no more than one 
T4 molecule at a time [17].  
Retinol (vitamin A) circulates in blood, bound to retinol binding protein (forming holo-RBP) 
which is found in complex with TTR.  This association functions to facilitate RBP release from 
its site of synthesis in the endoplasmic reticulum and to prevent renal filtration of RBP [18, 19].  
The presence of retinol bound to RBP is essential for the formation of a stable complex with 
TTR [20].  Structural studies revealed that the RBP binding site on TTR is orthogonal to TTR 
T4-binding pockets (Figure 1.2) [21].  In plasma, RBP binds to TTR in 1:1 molar ratio due to 
limited concentration of RBP available.  However, in vitro studies have shown that one TTR 
tetramer can bind up to two RBP molecules in presence of higher RBP concentration [1].  
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TTR as protease.  Apart from being a transporter of T4 and RBP, TTR has been identified to 
have proteolytic activity.  A fraction of TTR is known to associate with low density (LDL) and 
high density lipoproteins (HDL) and about  1–2 % of the total circulating plasma TTR is bound 
to apoA-I, a major HDL apolipoprotein [14].  Incubation of TTR and apoA-I under physiological 
conditions resulted in the cleavage of C-terminus of apoA-I.  This cleavage by TTR reduces the 
ability of apoA-I to promote cholesterol efflux and increases apoA-I amyloidogenicity resulting 
in the development of atherosclerosis.  
Recently, TTR has shown to have protective effect against amyloid beta (Aβ) deposition in 
Alzheimer’s disease (AD) [22].  Studies have shown that TTR could bind and cleave soluble Aβ 
and prevents the Aβ amyloid fibril formation in vitro [22].  TTR cleaves Aβ in multiple positions 
generating shorter Aβ peptides displaying lower amyloidogenic potential.  Also, TTR was able to 
degrade aggregated forms of Aβ and may contribute in maintenance of normal Aβ levels in the 
brain.  Among others, TTR is able to cleave neuropeptide Y (NPY) and may also contribute to 
neuropeptide homeostasis [23]. 
Miscellaneous.  Several other physiological ligands were identified as TTR ligands (e.g.  
norepinephrine oxidation products, yellow compounds (carotenoids) like lutein and pterin, 
proteoglycans like perlecan, Lysosome-Associated Membrane Proteins (LAMP-1), 
Metallothioneins (MT2), flavonoid and xanthone derivatives) [14].  
21 
 
 
 
 
 
 
 
 
 
Figure 1.2 TTR bound to T4 and holo-Retinol–binding protein (holo-RBP). 
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Chapter 2: Preclinical Evaluation of AG10, a Stabilizer of Transthyretin 
2.1 Introduction 
The systemic amyloidoses are a group of diseases that are caused by protein aggregation, 
including amyloid fibril formation, in soft tissue, nervous system, and solid organs [24, 25].  
TTR is one of more than 30 proteins whose aggregation can cause disease by a gain-of-toxic 
function mechanism [26].  Dissociation of the TTR-tetramer at the T4-binding interface, which 
generates dimers that rapidly dissociate into amyloidogenic monomers, is the rate-limiting step 
during TTR misfolding and amyloid formation (Figure 2.1) [27-29].  
There are more than 100 known amyloidogenic mutations in TTR, which segregate into 
ethnic and geographic groupings [30, 31].  Point mutations in TTR promote amyloidogenesis 
either by lowering its thermodynamic stability or through decreasing the kinetic barrier for 
tetramer dissociation, or both (Figure 2.1 and 2.2) [32].  These mutations lead to hereditary TTR 
amyloidoses such as familial amyloid polyneuropathy (FAP) [33, 34] and familial amyloid 
cardiomyopathy (FAC) [35-37], which are autosomal dominant conditions with varying ages of 
onset and penetrance depending on the TTR mutation and ethnic background of the carriers 
(summarized in Figure 2.1).  One of the clinically most important FAP-causing TTR mutations is 
the thermodynamically destabilized Valine to Methionine mutation at position 30 (V30M-TTR) 
[38, 39].  The most common TTR variant with almost exclusive cardiac involvement is the 
kinetically destabilized Valine to Isoleucine mutation at position 122 (V122I-TTR) [32, 40].  
Although the V122I-TTR monomer has similar stability to the WT-TTR monomer, the tetramer 
dissociates 3-fold faster under physiological conditions (Figure 2.1) [40, 41].  This allele occurs 
in 3.4% of African-Americans (~1.3 million people) and is hypothesized to contribute to the 
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increased prevalence of heart failure among African Americans [35-37, 40, 42].  WT-TTR 
aggregation underlies the development of senile systemic amyloidosis (SSA), a condition that 
affects up to 10−20 % of the population over age 65, which in some patients leads to progressive 
congestive heart failure [43, 44].  Both FAC and SSA are clinically important diseases that might 
be underappreciated and misdiagnosed as hypertensive heart disease [29, 42]. 
Additionally, it is important to mention two TTR variants, R104H and T119M, which have 
been shown to hyper-stabilize heterotetramers composed of these variants and either WT-TTR or 
mutant TTR, preventing amyloidogenesis in vitro [39].  Individuals who are compound 
heterozygous for both the T119M variant and the polyneuropathy associated V30M-TTR 
mutation present a more benign evolution of FAP or no disease compared to kindred carrying the 
V30M-TTR mutation alone [73].  In addition, carriage of the T119M variant alone has been 
correlated with a decreased risk of cerebrovascular disease and increased life expectancy in the 
general population by 5-10 years [39].  Similar effects have been described for the R104H-TTR 
variant which is found in compound heterozygous Japanese individuals expressing both R104H 
and V30M-TTR.  The trans-suppressor effects of R104H and T119M are based on different 
mechanisms [28].  While the T119M kinetically stabilizes the quaternary structure of TTR, the 
R104H variant is thermodynamically stabilized.  Therefore, the stabilizing effect of the T119M 
mutation is much greater than that of R104H, which only modestly protects against TTR 
dissociation and aggregation in vitro.  Consequently, the R104H variant may only suppress 
disease pathology in compound heterozygotes expressing mildly destabilizing TTR variant [29]. 
There are currently no effective, targeted medical therapies approved for FAC, and it is 
generally treated supportively.  One approach for targeting TTR amyloidosis is by suppressing 
TTR expression using small interfering RNA (siRNA) [45].  However, a phase 3 trial of the 
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siRNA revusiran (NCT02319005) for FAC was terminated prematurely and the program was 
discontinued following the disclosure of excess mortality with active treatment compared to 
placebo (17 of 19 deaths).  No such increased risk has been reported with patisiran, an alternative 
TTR siRNA under development for FAP [46].  Kinetic stabilization of the native tetrameric 
structure of TTR by interallelic trans suppression in compound heterozygote patients, who carry 
both the destabilizing V30M as well as a second, disease suppressing mutation (T119M) [47], or 
by small molecule occupancy of the T4-binding sites [3, 28, 34], raises the dissociative transition 
state energy and prevents amyloidosis (Figure 2.1).  Recently, clinical trials on tafamidis, a TTR 
kinetic stabilizer, indicated that it slows the progression of early stage neuropathy in FAP 
patients [48].  The non-steroidal anti-inflammatory drug (NSAID) diflunisal is another drug 
undergoing clinical trials for patients with FAP [49, 50], but its use may be contraindicated in 
patients with FAC due to the inhibition of cyclooxygenase (COX) enzymes [42, 51].  The 
catecol-O- methyltransferase (COMT) inhibitor tolcapone is another repurposed drug that is 
undergoing clinical trials for FAP [52].  However, tolcapone has previously demonstrated 
significant risk for fulminant liver failure and as a result carries a boxed warning [53].  At 
present, no FDA-approved drugs for prevention or treatment of FAC or SSA are available and 
the therapy for most patients is confined to symptomatic relief.  Liver transplantation, which 
removes the source of the mutated protein, has been the treatment of choice for hereditary TTR 
amyloidoses [54].  Combined liver and heart transplantation is performed as a palliative measure 
for a subset of FAC patients [55].  The risk and cost of organ transplantation is substantial and 
transplant patients require lifelong use of immune-suppressive drugs leading to morbidity.  For 
these reasons, there is an urgent need for a pharmacologic treatment of TTR cardiomyopathy.  
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Previously, the first high-throughput screen (HTS) for TTR ligands was reported [56], which 
enabled the identification of a variety of potent and structurally diverse TTR kinetic stabilizers 
[3].  In comparison to the clinical candidates tafamidis and diflunisal, our lab found that one of 
the analogues of 1, AG10, is a highly effective and selective stabilizer of both WT and V122I-
TTR.  AG10 was evaluated for its ability to bind serum protein transthyretin under various 
conditions.  Also, initial pharmacokinetic and toxicology studies were performed for AG10; 
these results are detailed in our labs’ previous publication [3].  Using published assays: the 
fluorescence polarization assay and the fluorescence probe exclusion assay, AG10 was 
determined to bind specifically and with high affinity to WT-TTR and mutant TTR (TTRmut) in 
buffer and human serum (FP and FPE probes, respectively; Figure 2.3).  X-Ray crystallography 
also revealed important insights into the mechanism of how AG10 is able to bind V122I-TTR 
with high affinity and to kinetically stabilize the tetramer [48].  The oral bioavailability, lack of 
toxicity in rodents, and additional favorable pharmacokinetic properties make AG10 a very 
promising candidate compound for treatment of TTR amyloidoses.  This chapter is focused on 
the continued evaluation of AG10 as a potential therapy for familial amyloid cardiomyopathy 
and is marked by its entrance into Phase I clinical trials. 
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Figure 2.1 The TTR amyloidogenesis cascade and a table summarizing TTR-mediated 
amyloidoses.  TTR amyloidoses require rate-limiting tetramer dissociation to dimers, followed 
by dissociation into monomers before partial unfolding of monomers yields the aggregation-
prone amyloidogenic intermediate.  The amyloidogenic intermediate can misassemble to form a 
variety of toxic aggregates, including amyloid fibrils.  Disease-associated destabilizing mutations 
can kinetically or thermodynamically destabilize TTR.  Kinetic stabilization can be achieved 
through trans-allelic suppression with the kinetically stabilized T119M-TTR, binding to T4 or 
other small molecules (Lower Left).   
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Figure 2.2 Structure of TTR shown as backbone ribbon representation with each of the 
monomers individually colored (2ROX) [13].  Thyroxine (T4) shown as ball and stick bound to 
the two T4-binding sites kinetically stabilizing the weaker dimer-dimer interface.  Black spheres 
represent the Cα positions of amino-acid mutations that alter the TTR tetramer stability either 
kinetically or thermodynamically. 
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Figure 2.3 Chemical structures of Fluorescence Polarization (FP)-probe 2 and covalent 
fluorescence probe 3. 
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2.2 Previous AG10 Characterization and Evaluation 
To fully understand the focus of my work, it’s necessary to review the work done previously 
to characterize AG10 and distinguish its potential as a TTR-stabilizing molecule.  This work was 
carried out mostly by my former labmate, Dr. Sravan Penchala, and my former colleague, Dr. Yu 
Wang (this statement applies to all work and figures listed in this section).  
To stabilize TTR tetramers in FAC and SSA patients, small molecules must selectively bind 
to TTR in the presence of more than 4,000 other serum proteins.  We examined the selectivity of 
AG10 for WT-TTR and V122I-TTR in human serum employing a ligand competition assay 
using covalent probe 3 (Figure 2.6) [57].  Probe 3 binds selectively to TTR in serum and then 
covalently modifies K15, creating a fluorescent conjugate [57].  Ligands that bind selectively to 
TTR in serum decrease the binding of probe 3 to TTR, decreasing the fluorescence.  However, in 
addition to selectivity, this assay depends also on the relative affinity of probe 3 and the test 
compound for the TTR binding sites, especially the second binding site (given that generally Kd2 
> Kd1).  Nevertheless, empirically, the results of the probe 3 competition assay at 3 h [57] 
correlate well with other direct measures of selectivity, such as the number of equivalents of 
small molecule that co-immunoprecipitate (IP) with TTR from biological fluids [16].  
Compounds (10 µM) were incubated with human serum (WT- or V122I-TTR concentration 
~5 µM) in the presence of probe 3 (3.6 µM).  The rate of TTR covalent conjugate formation was 
highest for diflunisal (>95 % probe binding relative to control), which binds weakly to WT-TTR 
[29] (Figure 2.10) and whose Cmax when orally dosed far exceeds 10 µM [16].  AG10 performs 
better in this assay in serum (3.1 ± 2.9 % probe binding after 6 h; Figure 2.10) than tafamidis and 
T4 (70.5 ± 1.4 % and 49.5 ± 2.6 % probe binding after 6 h, respectively.  In addition, binding of 
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AG10 to V122I-TTR in FAC patient serum was also very selective (6.9 ± 1.6 % probe binding) 
(Figure 2.11). 
These results from the probe 3 assay indicate that AG10 is highly selective for TTR in 
biological fluids.  However, the larger difference between AG10 and tafamidis in this assay 
corresponds to a smaller difference in other measures of selectivity, such as stabilization of 
serum TTR following acid-mediated denaturation (Figure 2.11) [3].  Using the previously 
established linear relationship between the probe 3 assay and the IP-based selectivity assays, we 
can estimate the selectivity of AG10 for TTR (in the IP assay, selectivity values range from 0 to 
2 equivalents of small molecule per TTR tetramer, with 0 equivalents indicating no selectivity 
and 2 equivalents indicating perfect selectivity for TTR [3].  The fluorescence at 3h from probe 3 
assay for AG10 (<1 % of control; Figure 2.10) and tafamidis (44.2 ± 3 % of control; Figure 2.10) 
correspond to IP selectivity values of 1.55 for AG10 and 0.7 for tafamidis (which is close to its 
measured value of 0.81) [3, 34].  By this measure, the dramatic difference of AG10 and tafamidis 
in the probe 3 assay (0 ± 2.5 % vs. 44.2 ± 3 %  probe 3 binding after 3 h, respectively) 
corresponds to a somewhat smaller difference in calculated selectivity (~1.55 vs. 0.81) [3].  
Nevertheless, it is clear that AG10 binds more selectively to TTR in serum than tafamidis.  The 
higher selectivity of AG10 is also demonstrated through serum stabilization assays as indicated 
in the western blots shown in Figure 2.21 and 2.22. 
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Figure 2.4 AG10 binds selectively to TTR in human serum.  (A) Fluorescence change caused by 
modification of TTR in human serum by covalent probe 3 monitored for 6 h in the presence of 
probe alone (black circles) or probe and TTR ligands (colors).  (B) Percentage of covalent probe 
binding to TTR in the presence of ligands measured after 6 h of incubation relative to probe 
alone.  (The lower the binding of the probe, the higher the binding selectivity of the ligand to 
TTR.) Each bar shows the mean ± SD of three replicates.  *Performed by Dr. Sravan Penchala 
(3). 
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Figure 2.5 AG10 is selective to V122I-TTR in FAC patient’s serum.  Fluorescence change due to 
modification of V122I-TTR in patient’s serum by covalent probe 3 monitored for 6 h in the 
presence of probe alone (black circles) or probe and TTR ligands (colors).  Each bar shows the 
mean ± SD of three replicates. *Performed by Dr. Sravan Penchala (3). 
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Figure 2.6 Stabilization of WT-TTR in serum against acid-mediated denaturation in the presence 
of AG10 and Tafamidis [3].  Serum samples were incubated (with DMSO, AG10, or tafamidis) 
in acetate buffer (pH 4.0) for the desired time period (0 and 72 h) before crosslinking and 
immunoblotting.  (A) The shown blot is representative of four independent blots.  (B) Error bars 
indicate standard error of the mean (SEM, n = 4).  *The experiment was performed by Dr. Yu 
Wang from Dr. William Chan Lab, University of the Pacific, Stockton, California (3). 
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Figure 2.7 Stabilization of V122I-TTR in serum from two patients with FAC against acid-
mediated denaturation in the presence of AG10 and Tafamidis [3].  Stabilization effect of 
tafamidis and AG10 on serum from a heterozygous patient with FAC (heterozygous V122I/WT-
TTR, African American, male, age 56 y) at 0 h (A and B) and after 72 h (C and D).  (E and F) 
Stabilization effect of tafamidis and AG10 on serum from a homozygous patient with FAC 
(homozygous V122I-TTR, Caucasian, female, age 62 y).  Error bars represent SEM of three 
replicates.  *The experiment was performed by Dr. Yu Wang from Dr. William Chan Lab, 
University of the Pacific, Stockton, California (3). 
  
35 
 
 
 
 
 
 
 
 
 
Figure 2.8 Assessment of the binding affinity of AG10 and Tafamidis to TTR by ITC. 
Calorimetric titration of AG10 (Kd1 = 4.8 nM, Kd2 = 314 nM) and Tafamidis (Kd1 = 4.4 nM, Kd2 
= 280 nM) against TTR.  Raw data (upper) and integrated heats (lower) from the titration of TTR 
(2 μM) with AG10 (25 μM). *Performed by Dr. Sravan Penchala (3). 
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2.3 Results 
Project goal statement.  Following the initial characterization and evaluation of AG10, of 
which I took small part, a more in-depth study of AG10 was undertaken in order to analyze 
critical features of AG10 and to determine why it was outcompeting all other TTR stabilizers.  
To achieve this end, my labmates and I participated in a coordinated effort to assay AG10 under 
various conditions listed presently. 
AG10 binding to TTR is enthalpically driven. In order to gain insight into the mode of 
binding and stabilization of TTR by the small molecules, we compared the binding affinity of 
AG10, tafamidis, diflunisal and tolcapone.  The Kd for binding of a stabilizer to TTR is 
represented by the change in Gibbs free energy (ΔG), where ΔG = ΔH – TΔS.  By analyzing the 
thermodynamic signature of each molecule, we assessed the relative contributions of enthalpic 
(ΔH; representing the formation or breaking of chemical bonds) and entropic forces (ΔS; 
frequently dominated and favored by release of bound water molecule due to hydrophobic 
interactions).  We first tested the binding affinity to TTR in buffer at physiological pH using 
fluorescence polarization (FP; Figure 2.3) [56].  The majority of TTR stabilizers bind to the two 
T4 binding sites of TTR with negative cooperativity and therefore the apparent binding constant 
(Kapp) obtained by FP represents a combination of both Kd1 and Kd2.  The binding affinity of 
AG10 to WT-TTR (Kapp = 47 ± 13 nM) was comparable to that of tafamidis (Kapp = 63 ± 19 nM) 
and tolcapone (Kapp = 65 ± 31 nM) (Figure 2.9).  The binding affinity of diflunisal to TTR was 
significantly lower than that of the other molecules tested (Kapp = 200 ± 65 nM).  These data 
correlate very well with published results where the Kd values were measured using isothermal 
titration calorimetry (ITC) (Table 1) [58-60].  
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Despite the similar binding affinity of AG10, tafamidis, and tolcapone to TTR in buffer (i.e., 
similar ΔG values), their binding energetics to TTR are notably different.  Whereas AG10 
binding is almost entirely enthalpically driven (enthalpy change, ΔH1 = −13.60 kcal/mol, entropy 
change, TΔS1 = −2.26 kcal/mol), tafamidis binding is approximately 50% entropic and 50% 
enthalpic (ΔH1 = −5.00 kcal/mol and TΔS1 = 6.39 kcal/mol) and tolcapone binding is 20% 
entropic and 80% enthalpic (ΔH1 = −8.7 kcal/mol and TΔS1 = 1.8 kcal/mol) (Table 1).  
Tafamidis’ significantly driven entropy binding to TTR is predicted based on its high 
lipophilicity (ClogP = 4.99).  On the other hand, AG10 has unfavorable entropic binding energy 
towards TTR (TΔS1 = -2.26 kcal/mol) due to its higher polarity (ClogP = 2.78) compared to other 
TTR stabilizers.  Thus the enthalpically driven binding of AG10 to TTR (as a result of formation 
of a number of chemical bonds with TTR) is likely the primary driver of its tight binding and 
highly efficient stabilizing activity towards TTR compared to other stabilizers. 
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Figure 2.9 Fluorescence polarization (FP) assay performed in buffer with purified human 
TTRwt. The Kapp values were calculated by modified Cheng-Prusoff equation 
(Kapp=IC50/(1+([competitor]/competitor Kd)) from IC50 values obtained by four parameter 
variable slope fit using the equation: Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-
X)*HillSlope)). 
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Table 2.1 Comparison of affinity and binding energy of stabilizers to TTRwt 
          
 FP (nM) ITC (nM)a ITC derived binding 
parameters 
 
  Kapp  Kd1 Kd2 ΔG1 ΔH1 TΔS1   ClogP 
          
AG10 47.2  4.8       314 -11.34 -13.6 -2.26   2.78 
          
Tafamidis 62.9  4.4       280 -11.39 -5.0  6.39   4.99 
          
Diflunisal 200.0  75      1110 -8.50 -7.8   0.7   4.39 
          
Tolcapone 65.4  21        58 -10.50 -8.7   1.8   3.24 
          
a Kd from ITC values as reported earlier (references 39, 41, & 43)     
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AG10’s binding to TTR mimics the protective T119M variant.  Our co-crystal structure 
of AG10 bound to TTR demonstrated that the strong enthalpic binding of AG10 to TTR is driven 
by formation of a network of hydrogen bonds and salt bridges within the T4 binding sites of TTR 
[3].  Despite the similar biochemical binding affinities of AG10 and tafamidis, we have shown 
earlier that at a substoichiometric ratio, AG10 demonstrated significantly higher efficacy than 
tafamidis in inhibiting amyloidogenesis of wild-type or V122I variant TTR in buffer at 
physiologic pH.  We hypothesized that this could be the result of the network of interactions that 
AG10 forms in the T4 binding pocket [3]. 
We analyzed the reported co-crystal structures of other stabilizers with TTR to highlight the 
critical functional groups within the T4 binding sites of TTR which are important for its 
stabilization (Figure 2.10 and 2.11); modelling studies performed by Dr. Hyun Joo, University of 
the Pacific.  The carboxylic acid moieties on AG10, tafamidis, diflunisal, and the hydroxyl group 
on tolcapone make electrostatic interactions with the ɛ-amino groups of K15 and K15′ at the 
periphery of the T4 binding sites [3, 52, 61].  Depending on intermolecular separations as 
estimated by these X-ray crystallographic studies, these interactions vary in their strength and/or 
the requirement for intervening water molecules to effect an electrostatic interaction that varies 
in its intrinsic strength or affinity.  In addition to these interactions with the carboxylic acid 
moiety, the major difference in the mode of binding of these compounds is the additional ability 
of AG10 to form two hydrogen bonds with both serines S117 and S117′ of adjacent subunits 
deep within the inner cavity of the T4 binding site (Figure 2.10a and 2.11a).  These additional 
electrostatic interactions are likely to be responsible for the driving force for the dominant 
enthalpic binding of AG10 to TTR.  Remarkably, similar interactions have been reported within 
the inner cavity of the kinetically stabilizing trans-suppressor T119M variant (Figure 2.10b and 
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2.11b) [62, 63].  The T119M mutation lowers tetramer dissociation (40-fold slower dissociation 
rate than TTRwt) and amyloidogenesis by increasing the kinetic barrier for TTR tetramer 
dissociation [39].  Based on reported crystal structures, no major conformational changes were 
observed between the T119M variant TTR compared to TTRwt [62].  The two S117 hydroxyl 
groups from monomers A and B in T119M variant TTR form direct hydrogen bonds (distance 
between the two S117 residues is ~2.8 Å), which are not observed in TTRwt (distance ~6.0 Å) 
(Figure 2.10c and 2.11c).  These unique hydrogen bonds lead to closer contacts between the two 
dimers within the TTR tetramer (distance between S117 and S117’ is ~4.8 Å compared to ~5.3 Å 
for TTRwt).  Interestingly, the distance between the S117 and S117’ residues in the 
thermodynamically stabilized R104H variant, which does not involve kinetic stabilization of the 
tetrameric TTR, is similar to that of TTRwt (distance between the two S117 is ~5.4-6.2 Å, Figure 
2.12d) [64, 65].  The lack of hydrogen bonding between the hydroxyl groups of S117 and S117’ 
in the R104H variant highlights the importance of these hydrogen bonds in the anti-
amyloidogenic and disease suppressing effects of kinetically stabilizing the TTR tetramer in the 
T119M variant; as previously noted, R104H is a less potent trans-suppressor mutant than 
T119M. 
By forming two direct hydrogen bonds with S117 and S117’ in the TTR tetramer (distance 
between the pyrazole nitrogens and the oxygens of S117/S117’ is ~2.8 Å), AG10 creates a bridge 
bolstering the stability of the weaker dimer-dimer interface (resulting in slowing of the rate-
limiting step in the TTR amyloidogenic cascade) (Figure 2.10a and 2.11a).  By comparison, 
tafamidis does not demonstrate any interaction with S117/S117’ of TTR and the distance 
between S117 and S117’ on the two dimers is ~5.5 Å (Figure 2.10d and 2.11d) compared to 
~4.65 Å for AG10 [3, 66].  At these larger separations, the strength of the hydrogen bond decays 
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slowly at a rate proportional to the inverse distance between the hydrogen donor and acceptor.  
Therefore, for every single distance unit increase between the donor and acceptor past ~3Å, the 
binding energy decreases by approximately half [67].  The extensive network of hydrogen bonds 
that two molecules of AG10 form by binding to the two T4 binding sites residues of TTR 
apparently works synergistically to draw both dimers and monomers toward the center of the 
protein (Figure 2.11a).  This may also be the reason for the ability of AG10 to occupy and 
stabilize a major proportion of TTR at a molar ratio of 1:1 AG10 to TTR tetramer [3].  
Importantly, AG10 is the only known TTR stabilizer that is capable of simultaneously forming 
both electrostatic interactions at the K15 residues and two hydrogen bonds with the S117/S117’ 
amino acid residues deep within the T4 binding sites of TTR.  
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Figure 2.10 Crystal structures highlighting similar interactions caused by the T119M mutation 
and binding of AG10 to TTR.  (a) Quaternary structure of AG10 bound to V122I-TTR (PDB: 
4HIQ[3]) shown as a ribbon representation with monomers colored individually.  Close-up views 
of one of the two identical T4 binding sites with different colored ribbons for the two monomers 
of the tetramer composing the binding site.  Key salt bridges between the carboxyl group of 
AG10 and K15/15’ and hydrogen bonds between the pyrazole ring and S117/117’ are 
highlighted by dashed lines.  (b) Crystal structure of the stabilizing T119M-TTR variant (PDB: 
1FHN[62]) with dashed lines highlighting key interactions between the hydroxyl groups of S117 
and S117’.  (c) Crystal structure of TTRwt (PDB: 3CFM [65]).  (d) Crystal structure of the 
tafamidis bound to V122I-TTR (PDB: 4HIS [3]). *Performed by Dr. Hyun Joo. 
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Figure 2.11 Expanded view of Figure 2.10 highlighting the interactions between the hydroxyl 
groups of S117 and S117’ in the four monomers of TTR. 
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Figure 2.12 Crystal structures comparing the interactions caused by the T119M mutation and 
AG10 binding to TTR relative to that of TTRwt and R104H-TTR.  (a) Quaternary structure of 
AG10 bound to V122I-TTR (PDB: 4HIQ [3]) shown as a ribbon representation with monomers 
colored individually.  Close-up views of one of the two identical T4 binding sites with different 
colored ribbons for the two monomers of the tetramer composing the binding site.  Key salt 
bridges between the carboxyl group of AG10 and K15/15’ and hydrogen bonds between the 
pyrazole ring and S117/117’ are highlighted by dashed lines.  (b) Crystal structure of the 
stabilizing T119M-TTR variant (PDB: 1FHN[62]) with dashed lines highlighting the key 
interactions between the hydroxyl groups of S117 and S117’.  (c) Crystal structure of TTRwt 
(PDB: 3CFM [65]).  (d) Crystal structure of thermodynamically stabilized R104H-TTR (PDB: 
1X7T [64]).  
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Characterization of the key functional groups of AG10 important for mimicking the 
T119M variant.  In order to investigate the contribution of each of the functional groups of 
AG10 to TTR binding and stabilization, we synthesized and tested three AG10 analogues and 
evaluated their ability to bind and stabilize TTR (Figure 2.13 and Figure 2.14).  The carboxylic 
acid moiety on the para-fluoro-aryl ring of AG10 makes electrostatic interactions directly with 
the ϵ-amino groups of K15 and K15′ at the periphery of the T4 binding site which serve to close 
the T4 pocket around AG10 and partially shield it from solvent.  We first synthesized a methyl-
ester analogue of AG10 (compound 1, Fig. 2.14a) to test the effect of modifying the two salt 
bridges that AG10 forms at the periphery of the T4 binding site.  In the FP assay, compound 1 
displayed significantly lower affinity (Kapp = 252 ± 86 nM) to TTR in buffer compared to AG10 
(Kapp = 47 ± 13 nM).  This could be explained by the lower strength of potential hydrogen bonds 
between the ester group of 1 and K15/K15’ compared to the salt bridge in AG10 (Figure 2.15b).  
The potency of compound 1 for occupying and stabilizing TTRwt in human serum was evaluated 
using a previously reported fluorescence probe exclusion assay (FPE) [57, 68], which utilizes a 
covalent probe (FPE probe; Fig. 2.3).  The FPE probe is a fluorogenic compound that binds 
selectively to the ϵ-amino group of K15 within the T4 binding sites of TTR in serum under 
physiological conditions.  The fluorescence of FPE probe binding to TTR tetramer in the 
presence of a stabilizer is a measure of the binding affinity and selectivity of the stabilizer for 
TTR in serum (i.e. the lower the fluorescence of the probe, the higher the potency of TTR 
binding).  In the FPE assay, compound 1 displayed reduced TTR occupancy in human serum 
(78.3 ± 2.6%) compared to AG10 at the same concentration (10 µM) (Fig. 2.14c,d).  
The 3,5-dimethyl-1H-pyrazole ring of AG10 sits deep within the inner cavity of the T4 
binding site and forms two hydrogen bonds with the S117 and S117′ of adjacent subunits [3].  By 
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blocking these interactions, we can effectively observe their enthalpic contribution through the 
FP and FPE assays, respectively.  To test this hypothesis, we synthesized compound 2 which has 
an N-methyl pyrazole.  The N-methyl group would restrict the pyrazole ring of 2 to forming only 
one hydrogen bond with one of the adjacent TTR subunits (Fig. 2.15c).  We also synthesized 
compound 3 where the dimethyl pyrazole of AG10 was replaced with diethyl pyrazole.  
Modeling studies suggested that the bulk of the diethyl groups would prevent the molecules from 
reaching deep in the T4 binding site, thereby decreasing its ability to potentially form any 
hydrogen bonds with S117/S117’ (Fig. 2.15d).  As predicted by modeling, both 2 (Kapp = 658 ± 
168 nM) and 3 (1253 ± 188 nM) (Fig. 2.14b) showed greatly reduced binding affinity to TTR in 
buffer.  This reduced affinity also translated into a significant decrease in TTR occupancy in 
serum, especially for compound 3 (45.6 ± 2.5% TTR occupancy for 2 and 13.6 ± 3.9% TTR 
occupancy for 3) (Fig. 2.14c,d).  These results highlight the crucial role played by the pyrazole 
ring and the importance of the hydrogen bonds it forms with the two TTR dimers, mimicking the 
interactions in the protective T119M TTR mutation, and enhancing the kinetic stability of the 
TTR tetramer. 
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Figure 2.13 Synthesis of AG10 analogues 1, 2, and 3.  a) i. acetylacetone, DBU, benzene, rt, 3 
days; ii. hydrazine hydrate, ethanol, 90oC, 4 h; b) i. NaH, MeI, DMF rt, 16 h; ii. NaOH, 
MeOH/water, 50oC, 14 h; c) i. 3,5-Heptanedione, DBU, benzene, rt, 3 days; ii. hydrazine 
hydrate, ethanol, 90oC, 4 h; d) NaOH, MeOH/water, 50oC, 14 h. 
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Figure 2.14 The pyrazole ring of AG10 is important for effective binding to TTR.  (a) Chemical 
structures of AG10 analogues (1, 2, and 3).  (b) Fluorescence polarization (FP) assay performed 
in buffer with human TTRwt.  The Kapp values for AG10 analogues were calculated by modified 
Cheng-Prusoff equation from IC50 values obtained by four parameter variable slope fit.  (c) 
Fluorescence change caused by modification of TTRwt in human serum by FPE probe monitored 
for 6 hr in the presence of probe alone (black circles) or probe and AG10 analogues (colors).  (d) 
Percent occupancy of TTR in human serum by AG10 analogues (at 10 µM) in the presence of 
FPE probe measured after 3 hr of incubation relative to probe alone. Error bars indicate SD (n = 
4). 
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Figure 2.15 In silico docking study of AG10 analogues 1, 2, and 3.  (a) Co-crystal structure of 
AG10 bound to TTR used for the docking experiment.  (b) Analogue 1 is the methyl-ester form 
of AG10 that cannot form salt bridge with K15/15’.  (c) Analogue 2 is the methyl-pyrazole form 
of AG10 that can potentially form only one hydrogen bond with either K15 or K15’.  (d) 
Analogue 3 is the diethyl-pyrazole analogue of AG10 which affects both hydrogen bonds with 
S117/S117’.  
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AG10 is a more effective TTR stabilizer in serum than other stabilizers.  Previously we 
have shown that, at equimolar concentrations, AG10 was a more selective and potent TTR 
stabilizer than tafamidis [3].  There are no reports on simultaneously comparing the selectivity 
and efficacy of AG10 against the known clinically studied stabilizers (i.e., tafamidis, diflunisal, 
and tolcapone) at their reported concentrations in human trials.  We tested AG10 (at 10 µM) and 
other stabilizer compounds for their ability to stabilize TTRwt in human serum (TTR 
concentration ∼5 μM) at their reported maximum plasma concentrations (Cmax) (tafamidis ~20 
µM for 80 mg dose q.d.; diflunisal ~200 µM for 250 mg b.i.d; and tolcapone ~20 µM for 100 mg 
dose t.i.d.).  The Cmax for each stabilizer was selected as it represents the potential for maximal 
stabilization attainable during dosing in clinical trials (Fig. 2.16a,b).  Western blot analysis was 
used to measure the amount of intact TTR tetramer after 72 h of acid treatment in the presence 
and absence of stabilizers.  By using this previously described technique [3, 49, 59], we detected 
the TTR tetramer as well as tetrameric TTR bound to RBP.  At 10 μM (corresponds to 
AG10:TTR binding sites molar ratio of 1:1) AG10 completely stabilizes TTR in serum 
(%tetramer = 97.6 ± 9.4%) while the other compounds were able to stabilize ~72-82% of 
tetrameric TTR at maximal concentrations (Fig. 2.16a,b).  Even at lower concentrations, AG10 
was a more effective TTR stabilizer than other clinically studied stabilizers tested at higher 
concentrations. 
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Figure 2.16 AG10 is more efficient in occupying and stabilizing TTR in human serum compared 
to other TTR stabilizers.  (a) A representative western blot image for the stabilization of TTRwt 
in serum against acid-mediated denaturation in the presence of AG10 (10 µM) and other 
stabilizers (tested at their estimated therapeutic Cmax; tafamidis 20 µM; tolcapone 20 µM; 
diflunisal 200 µM).  Serum samples were incubated with DMSO or test compounds in acetate 
buffer (pH 4.0) for the desired time period (0 and 72 hr) before crosslinking and immunoblotting. 
Normalization with IgG was performed using IRdye800 goat anti-human IgG.   (b) The intensity 
of TTR bands (TTR tetramer and TTR bound to RBP, arrowhead) was quantified by using an 
Odyssey IR imaging system and reported as percentage of TTR tetramer, calculated as 100 × 
[(tetramer and tetramer + RBP density, 72 hr)/(tetramer and tetramer + RBP density of DMSO, 0 
hr)]. Bar graph representation of data obtained from western blot experiments. Error bars 
indicate SD (n = 3).  (c) Fluorescence change caused by modification of TTR in human serum by 
FPE probe monitored in the presence of probe alone (Control DMSO), AG10 (10 µM), or TTR 
stabilizers (at their estimated Cmax).  (d) Percent occupancy of TTR in human serum by 
stabilizers in the presence of FPE probe measured after 3 hr of incubation relative to probe alone.  
Error bars indicate SD (n = 4). 
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AG10 has high occupancy and selectivity for TTR in human serum.  To effectively 
stabilize TTR tetramers in vivo, stabilizers must demonstrate a favorable balance between 
achievable human plasma concentrations and binding selectivity for TTR in the presence of other 
serum proteins.  A recent study found that the enthalpy (i.e. ΔH) of ligands binding to TTR 
correlates better with selectivity for TTR in serum than Kd [69].  Ligands with more favorable 
(i.e. larger negative) ΔH had a proportionally higher TTR selectivity compared to ligands with a 
lower influence of ΔH.  Therefore, due to its high and predominantly enthalpic binding, AG10 is 
predicted to have high selectivity for TTR in serum.  The potency and selectivity of AG10 in 
occupying and stabilizing TTRwt in human serum was evaluated using the FPE assay described 
above.  The performance of AG10 in the FPE assay at 10 µM (%TTR occupancy 93.6 ± 2.1%) 
was significantly better than all other stabilizers (%TTR occupancy ~65-86%) at their reported, 
human Cmax (Fig. 2.16c,d).  The data from the FPE assay indicate that AG10 has higher 
selectivity to TTR compared to the other stabilizer compounds.  A linear correlation was 
reported between the extent of TTR–FPE probe fluorescence derived from FPE probe after a 3 hr 
competition and the previously reported stabilizing efficacy of kinetic stabilizers [57].  We also 
observed a very good correlation between TTR occupancy (obtained by FPE assay) and TTR 
stabilization (obtained by Western blot) when we evaluated the activity of AG10 (R2 = 1.0) (Fig. 
2.17).  For tafamidis, there was a good correlation (R2 = 0.87) for concentrations up to 10 µM, 
however, at higher concentrations there was a saturating effect in the FPE assay due to non-
specific binding to serum albumin (Fig. 2.17).  Therefore, the FPE assay is a simple assay that, in 
addition to determining TTR occupancy, may also predict TTR stabilization by ligands in human 
serum.  Our data show that, even at a lower concentration, AG10 outperforms the other tested 
TTR stabilizers.   
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Figure 2.17 Correlation between TTR occupancy and TTR stabilization.  A linear correlation 
was observed between the extent of TTR occupancy (measured by FPE assay) and TTR 
stabilization (measured by Western blot) by (a, b, c) AG10 (R2 = 1.0) and (d, e, f) tafamidis (R2 = 
0.87) in human serum with WT-TTR. Error bars indicate SD (n = 3).  
 
 
 
 
 
Concentration (µM)
%
 T
T
R
 O
c
c
u
p
a
n
c
y
1 5 10
0
20
40
60
80
100 AG10
Concentration ( µM)
%
 T
e
tr
a
m
e
ri
c
 S
ta
b
ili
z
a
ti
o
n
1 5 10
0
20
40
60
80
100 AG10
% TTR Occupancy
%
 T
e
tr
a
m
e
ri
c
 S
ta
b
ili
z
a
ti
o
n
0 20 40 60 80 100
0
20
40
60
80
100
Concentration ( µM)
%
 T
T
R
 O
c
c
u
p
a
n
c
y
1 5 10
0
20
40
60
80
100
Tafamidis
Concentration ( µM)
%
 T
e
tr
a
m
e
ri
c
 S
ta
b
ili
z
a
ti
o
n
1 5 10
0
20
40
60
80
100
Tafamidis
% TTR Occupancy
%
 T
e
tr
a
m
e
ri
c
 S
ta
b
ili
z
a
ti
o
n
0 20 40 60
0
20
40
60
a
b
55 
 
AG10 has higher selectivity for TTR over albumin.  Despite the similar in vitro binding 
affinity of tafamidis to TTR in buffer, it was not able to stabilize TTR to the same extent as 
AG10 even at a higher molar concentration of tafamidis in serum.  Thus, we explored the 
possibility that tafamidis has lower selectivity for binding to TTR in human serum.  We 
evaluated the dose-response relationship of AG10 and tafamidis to TTR in human serum using 
the FPE assay (Fig. 2.18).  AG10 showed a dose-responsive activity, with near complete 
stabilization at 10 µM of AG10.  Even at a substoichiometric concentration of 5 µM, AG10 was 
able to occupy and stabilize the majority of TTR (FPE: 69.2% TTR occupancy, Western Blot: 
74.5% stabilization) (Fig. 2.17).  In contrast, there was little improvement in the activity of 
tafamidis at concentrations above ~20 µM.  The higher selectivity of AG10 to TTR could be 
attributed to a number of properties, one of which may be that AG10 is more hydrophilic (ClogP 
~2.78) than tafamidis (ClogP ~4.99).  The higher lipophilicity of tafamidis would enhance its 
binding to human serum albumin (HSA), lowering the amount of tafamidis available for binding 
to TTR in serum. 
To confirm this hypothesis, mixtures of AG10 and tafamidis (30 µM), preincubated with 
albumin (at a physiological concentration of 600 µM), were subjected to gel filtration followed 
by dialysis.  At time 0 (immediately after gel filtration), more tafamidis was bound to albumin 
compared to AG10 (24.1 ± 1.1 µM and 18.3 ± 0.98 µM, respectively) (Fig. 2.19).  After dialysis 
over 24 hr, the concentration of bound AG10 (7.8 ± 0.1 µM) was lower than that for tafamidis 
(18.8 ± 2.1 µM).  These data showed that tafamidis has a higher binding affinity for albumin 
compared to AG10.  In addition, we dialyzed a mixture of AG10 and TTR (2:1 molar ratio; 10 
µM AG10 and 5 µM TTR).  The dissociation of AG10 from TTR was slow for the first six hours 
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(concentration at 6 hr is 6.1 µM, representing an AG10-TTR molar ratio of ~1.2:1), but 
maintained a 1:1 molar ratio over 24 hr (Fig. 2.19b).  
The selectivity of AG10 and tafamidis for binding to TTR in human serum was also 
evaluated using a modified FPE assay where the serum was replaced with purified human 
TTRwt in buffer (PBS buffer, pH 7.4).  In addition to purified TTR (5 µM), four separate 
representative and abundant plasma proteins were added to the FPE assay in buffer.  Addition of 
albumin, transferrin, fibrinogen or immunoglobulin (IgG) did not alter FPE probe binding to 
TTR or interfere with measurements related to binding and occupancy of AG10 (>97% TTR 
occupancy in the absence and presence of any of these proteins, Fig. 2.19c,d).  In contrast, we 
observed a significant decrease in TTR occupancy by tafamidis when albumin was present (37.6 
± 0.65% compared to 69.9 ± 0.62% in the absence of albumin) (Fig. 2.19e,f).  There was no 
major difference in %TTR occupancy when any of the other plasma proteins were present in 
addition to albumin (%TTR occupancy 34.7 ± 2.53%).  These data indicate that the potency of 
tafamidis observed in both the FPE and Western blot (Fig. 2.17 and 2.18) assays is limited to an 
important extent by off target binding of tafamidis to albumin.  
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Figure 2.18 Dose-response for TTR occupancy by AG10 and tafamidis in human serum.  Dose 
response of binding and stabilization of TTR by AG10 and tafamidis assayed by FPE assay in 
human serum with TTRwt: Fluorescence change caused by modification of TTR by FPE probe 
monitored in the presence of probe alone (Control DMSO, black circles) or by increasing 
concentrations of (a) AG10 or (c) tafamidis (colors).  Percent occupancy of TTR in human serum 
by increasing concentrations of (b) AG10 or (d) tafamidis in the presence of FPE probe 
measured after 3 hr of incubation relative to probe alone. Error bars indicate SD (n = 4). 
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Figure 2.19 AG10 binding selectivity to TTR is not affected by other human serum proteins.  (a) 
Gel filtration and dialysis assay for AG10 and tafamidis (30 µM) incubated with human serum 
albumin (600 µM).  The concentration of tafamidis bound to albumin after gel-filtration (i.e. 
dialysis time 0 hr) was normalized to 100%. Error bars indicate SEM (n = 3).  (b) 24 hr time-
course for dialysis of AG10 (10 µM) incubated with purified human TTR (5 µM).  Error bars 
indicate SEM (n = 3).  (c) Fluorescence change due to modification of purified human TTR (5 
µM) by FPE probe monitored for 6 hr in the presence of probe alone (black circles), probe plus 
albumin (600 µM) (black triangles), probe plus all [fibrinogen (5 µM), albumin (600 µM), IgG 
(70 µM), transferrin (25 µM)] (grey triangles); probe and AG10 (10 µM) (red squares) or probe 
and AG10 plus albumin (green diamonds), probe and AG10 plus all [fibrinogen (5 µM), albumin 
(600 µM) IgG (70 µM), transferrin (25 µM)] (blue circles).  (d) %TTR occupancy in buffer by 
AG10 analogues in the presence of FPE probe and other serum proteins measured after 3 hr of 
incubation relative to probe alone.  (e and f) same experiment described for AG10 was 
performed for tafamidis. Probe alone (black circles), probe plus albumin (600 µM) (black 
squares), probe plus all [fibrinogen (5 µM), albumin (600 µM), IgG (70 µM), transferrin (25 
µM)] (green diamonds); probe and tafamidis (10 µM) (blue triangles) or probe and tafamidis 
plus albumin (green diamonds), probe and tafamidis plus all [fibrinogen (5 µM), albumin (600 
µM) IgG (70 µM), transferrin (25 µM)] (blue circles).  Error bars indicate SD (n = 3). 
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Orally administered AG10 selectively binds to dog TTR.  No genetically modified mouse 
model which expresses the human V122I-TTR variant has been generated to date [70, 71].  In 
addition, the level of TTR overexpression required to observe TTR amyloid deposits in mouse 
can be very high unless generated on a murine TTR knockout background.  This is due to the 
intrinsically high stability of murine TTR.  Because of the stoichiometric requirements of 
stabilizer binding to TTR tetramer, the concentrations of administered agent required to stabilize 
transgenic human TTR are thus difficult to achieve in the reported mouse models [28].  
Currently, the efficacy of TTR stabilizers in occupying and stabilizing TTR is performed ex vivo 
on blood samples obtained from patients after dosing of the stabilizer.  Owing to the lack of a 
reliable nonclinical model that can faithfully recapitulate the ATTR-CM phenotype, we took an 
approach similar to that currently used in the clinic to examine the efficacy of AG10 vs other 
TTR kinetic stabilizers. 
We chose the healthy beagle dog as our experimental model for several reasons.  The 
structure and concentration (~4.6 µM, Figure 2.20) of TTR in dogs is similar to that in humans 
[72].  In addition, the sequence homology for human TTR and dog TTR at the amino acid level 
is 86%. Most of the sequence differences occur in peripheral loop regions, while all amino acids 
in the T4 binding sites, where AG10 and other stabilizers bind, are conserved between dog and 
human.  In addition, rabbit antiserum against human TTR cross reacts with dog TTR and rabbit 
antiserum against the dog TTR cross reacts with human TTR, indicating the presence of similar 
epitopes and conformation of proteins [72].  We evaluated the activity of AG10 and tafamidis in 
pooled dog serum using FPE and Western blot assays.  The differential in vitro TTR binding and 
stabilization concentration-effect relationships of AG10 vs tafamidis in both assays using dog 
serum was similar to those observed in human serum (Fig. 2.21).  Finally, we established that 
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AG10 is highly orally bioavailable across multiple nonhuman mammalian species, and the 
pharmacokinetic (PK) behavior of many small molecules in dog tends to be quite similar to that 
of the same compounds in human.  These features made the healthy canine a suitable system for 
subsequent investigations. 
We performed a 7 day repeat-dose, pharmacokinetic-pharmacodynamic (PK-PD) study in 
dogs wherein AG10 was administered daily by oral gavage.  The study included of a total of 16 
male (M) and 16 female (F) beagle dogs, separated into four treatment groups: (i) 6M/6F at 0 
mg/kg; (ii) 2M/2F at 50 mg/kg; (iii) 2M/2F at 100 mg/kg; and (iv) 6M/6F at 200 mg/kg.  The 
dogs were treated with vehicle or AG10 and timed serum samples were collected pre-dose on 
study day 1 (prior to any AG10 exposure), pre-dose on study day 7 (representing a trough 
concentration or Cmin at steady state), and at 1 hr post-dose on study day 7 (representing a peak 
concentration or Cmax at steady state).  The FPE assay was then performed by addition of the FPE 
probe to the serum samples and conducted under standardized conditions.  As expected, serum 
samples from dogs treated with vehicle alone and those collected prior to exposure to AG10 
showed no TTR occupancy (Fig. 2.22a,b).  Serum samples from AG10-treated dogs displayed a 
dose-proportional response at the estimated steady state Cmin (day 7 pre-dose; ~81-94% TTR 
occupancy), while all AG10 treated groups showed >97% TTR occupancy at the estimated 
steady state Cmax (day 7 post-dose) (Fig. 2.22a,b).   
We subsequently tested lower doses of AG10 to further explore the PK-PD (exposure-effect) 
relationship in order to identify a minimally effective dose of AG10 that may still effectively 
bind to and stabilize TTR.  We reasoned that this could serve as a guide for selecting a threshold 
dosing regimen required to attain effective TTR binding and stabilizing concentrations in ATTR-
CM patients.  Eight dogs, divided into two groups, received either 5 or 20 mg/kg AG10 as a 
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single oral dose.  Our results showed enhanced TTR occupancy in the serum from the 20 mg/kg 
vs. 5 mg/kg doses (Figure 2.22c,d, Fig. 2.23).  Importantly, our results showed that plasma 
concentration of AG10 correlates well with %TTR occupancy (Fig. 2.22c,d).  Both dog studies, 
single and multiple dose regimens, represent the first example of demonstrating nonclinical PK-
PD evaluation of ex vivo TTR occupancy by stabilizers using the FPE assay. 
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Figure 2.20 Determination of TTR Concentration in commercially available dog serum using 
ELISA.  Calibration curve generated by serial dilution of commercial dog serum according to kit 
protocol.  The concentration of TTR in dog serum was determined to be ~4.6 µM. 
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Figure 2.21 Activity of AG10 and tafamidis in the FPE assay performed with pooled dog serum.  
(a) Fluorescence change caused by modification of dog TTR in commercially available beagle 
dog serum by FPE probe monitored in the presence of probe alone (Control DMSO, black 
circles), AG10 (10 µM) or tafamidis (10 µM).  (b) Percent occupancy of dog TTR in dog serum 
by AG10 and tafamidis in the presence of FPE probe measured after 3 hr of incubation relative 
to probe alone. Error bars indicate SD (n = 4).  (c) Western blot image for the stabilization of 
TTR in pooled dog serum against acid-mediated denaturation in the presence of AG10 (10 µM) 
and tafamidis (10 µM).  Serum samples were incubated with DMSO or test compounds in 
acetate buffer (pH 4.0) for the desired time period (0 and 72 h) before crosslinking and 
immunoblotting.  (d) The intensity of dog TTR bands (TTR tetramer and TTR bound to RBP, 
arrowhead) was quantified by using an Odyssey IR imaging system and reported as percentage 
of TTR tetramer, calculated as 100 × [(tetramer and tetramer + RBP density, 72 h)/(tetramer and 
tetramer + RBP density of DMSO, 0 h)].  Bar graph representation of data obtained from western 
blot experiments. Error bars indicate SD (n = 3).   
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Figure 2.22 Orally administered AG10 is effective in binding and stabilizing TTR in dogs.  (a 
and b) Occupancy of TTR in beagle dogs after oral administration (q.d. for 7 days) of escalating 
doses of AG10.   Circles (●) indicate pre-dose day 1, squares (■) indicate pre-dose day 7 (AG10 
concentration at Cmin), and triangles (▲) indicate post-dose day 7 (AG10 concentration at Cmax). 
Four groups of animals were dosed: (i) 0 mg/kg (n=12, 6 males/6 females); (ii) 50 mg/kg (n=4, 2 
males/2 females); (iii) 100 mg/kg (n=4, 2 males/2 females); (iv) 200 mg/kg (n=12, 6 males/6 
females) (b) Bar graph representing TTR occupancy at 3 hr.  Error bars indicate SD (n = 3). (c 
and d) Pharmacokinetic-Pharmacodynamic (PK-PD) analysis of AG10 in dogs receiving a single 
oral dose of AG10 at (c) 5 mg/kg and (d) 20 mg/kg.  Scatterplot of concentration [AG10] vs. 
%TTR occupancy of serum samples obtained from dogs at various time points (n=4, 2 males/2 
females per dosing group).  *7-day study (a, b) performed by Arindom Pal. 
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Figure 2.23 Data used to generate the PK-PD in Fig. 2.22. Scatterplot of concentration [AG10] 
vs. %TTR occupancy in dog serum for 5 mg/kg (n=4, 2 males/2 females, left column) and 20 
mg/kg (n=4, 2 males/2 females, right column). Error bars indicate SD (n = 3).  
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2.4 Discussion 
TTR-related cardiomyopathy is an increasingly recognized cause of heart failure in a subset 
of patients who, at least at an early stage of their disease, otherwise may resemble a much larger 
group of patients with heart failure with preserved ejection fraction (HFpEF).  We compared the 
potency of known clinically studied small molecule stabilizers for TTR amyloidosis at their 
relevant plasma concentrations.  Even though many stabilizers have similar in vitro binding 
affinities (Kd), AG10 was the most effective stabilizer in serum.  It occupied and stabilized >95% 
TTR at 10 µM (1:1 ratio of AG10:TTR binding sites), while other compounds stabilized a 
maximum of ~80-85% of TTR at higher molar stoichiometry.  Our results show that Kd 
measurements in a purified protein experimental system did not fully predict the potency of a 
stabilizer in serum.  This agrees with previous reports which found that enthalpic forces are a 
more predictive parameter for selectivity towards TTR in serum [69].  
The trans-suppressor T119M mutation is a super-stabilizing variant compared to TTRwt (40-
fold slower dissociation) and is very effective in stabilizing hetero-tetrameric TTR species in 
vitro.  This variant effectively ameliorates disease progression and symptoms in compound 
heterozygous individuals carrying pathogenic, destabilizing mutations such as the V30M variant 
TTR [73].  The T119M substitution induces conformational changes that promote hydrogen 
bonding between the hydroxyl groups of adjacent S117 residues in T119M variant TTR 
monomers and lead to closer contacts between the two dimers within the tetramer [62].  These 
interactions and their consequences are neither observed in TTRwt nor in the thermodynamically 
stabilized, disease-protective R104H variant, leading us to conclude that they are exceptionally 
important for the kinetic stabilization of the TTR tetramer [62, 64, 65].  Our studies show that the 
mode of action of AG10 is through kinetic stabilization of TTR, which is similar to the 
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kinetically stabilizing T119M variant and not comparable to the thermodynamically stabilizing 
R104H.  When comparing the T119M mutation to the co-crystal structure of AG10 bound to the 
kinetically destabilized V122I variant TTR [3], the similarities of these critical intermolecular 
interactions are clear and allows us to conclude that AG10’s mode of binding, especially the 
hydrogen bonds with S117/S117’, leads to AG10’s superiority to other stabilizers in effectively 
stabilizing tetrameric TTR.  The experiments comparing closely related, structural analogues of 
AG10 highlight the important role of the pyrazole ring of AG10 in enthalpically driving the 
binding by forming multiple interactions with different subunits of TTR.  It is important to note 
that none of the other stabilizers has this unique interaction with the S117/S117’ residues at the 
bottom of the T4 binding pocket of TTR.  As we have shown previously with the V122I variant 
TTR, we propose that AG10 may effectively stabilize other TTR variants as well as it stabilizes 
TTRwt.  This should support a role for AG10 as an effective therapy for TTR-related 
amyloidosis across a spectrum of disease-promoting genotypes.  
There are a few examples where the binding of a small molecule to a known disease-causing 
target mimics a stabilizing mutation identified in that target.  The stabilizing effects of inositol 
tetraphosphate (IP4) binding to wild-type histone deacetylase 3 (HDAC3) have been shown to 
mimic a stabilizing point mutation in this protein involved in epigenetic regulation of gene 
expression [60].  Molecules with similar binding and stabilizing characteristics to AG10 could 
therefore potentially be useful for stabilizing multi-subunit protein complexes in certain diseases 
such as the α-synuclein tetramer in Parkinson disease [74].  
There are no suitable animal models that can predict clinical outcome for ATTR-CM.  
Therefore, we adapted clinical methods already in use to healthy beagle dogs to evaluate AG10 
efficacy in binding to and stabilizing tetrameric TTR.  These studies demonstrated superior 
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efficacy of AG10 in occupying and stabilizing TTR both in vitro and ex vivo following oral 
administration to dogs.  The results clearly demonstrate that orally administered AG10 results in 
predictable, dose-proportional plasma concentrations that effectively bind with high selectivity to 
TTR in dog serum.  The data from the repeat dose studies show that oral administration of AG10 
to steady state in dogs results in ~88-95% TTR occupancy at the expected Cmin and >95% TTR 
occupancy at Cmax, indicating both binding sites of the TTR tetramer are occupied by AG10 at 
dose levels of 50 mg/kg/d or greater.  The PK-PD study of single doses in dogs (5 and 20 mg/kg) 
demonstrated that the FPE assay was also capable of detecting differences in TTR occupancy by 
AG10 at lower circulating concentrations.  The similarity between dog and human TTR, and the 
expected similarity in PK behavior of many small molecules between dog and human, makes this 
nonclinical system suitable for evaluating the PK-PD of other potential TTR stabilizers.  We 
expect that these data will serve as a guide for selecting a dosing regimen that can safely attain 
effective TTR binding and stabilizing concentrations of AG10 in humans.  
2.5 Conclusion 
In summary, we performed a comprehensive comparison of the potency of AG10 compared 
to other TTR stabilizers that have already been evaluated in patients.  Oral dosing in the dog 
represents a simple, informative ex vivo model for exploring the nonclinical PK-PD relationships 
of small molecule TTR stabilizers such as AG10.  Importantly, the structural insights gained 
from analyzing crystal structures and functional groups of AG10 that are important for 
stabilizing TTR, and showing that they mimic the intermolecular interactions present in the 
T119M variant TTR, could potentially be beneficial for designing novel kinetic stabilizers for 
other amyloid diseases. 
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2.6 Methods 
Materials. Prealbumin from human plasma (human TTR) was purchased from Sigma.  
Diflunisal, Thyroxine (T4), and resveratrol were purchased from Fisher.  1H NMR and 13C NMR 
spectra were recorded on a Jeol JNM−ECA600 spectrometer and calibrated using residual 
undeuterated solvent as an internal reference.  High resolution mass spectra (HRMS) were 
determined by JEOL AccuTOF DART using helium as an ionization gas and polyethylene glycol 
(PEG) as an external calibrating agent.  HPLC analysis was performed on a Waters™ Alliance 
2790 system attached to Waters™ 2990 PDA detector operating between the UV ranges of 200 – 
400 nm.  Empower 2.0 data acquisition system was used for quantification purposes.  A 
Waters™ XBridge C18 column with L1 packing (4.6 X 150 mm, 5μm) was used at ambient 
temperature.  The mobile phase was composed of 23 % (v/v) acetonitrile in an aqueous solution 
containing 50 mM potassium phosphate (pH 3.2).  An isocratic separation was performed for 30 
min at a flow rate of 0.5 ml/min.  A small volume of 40 μl injection of each standard and/or 
sample was performed to obtain the chromatogram.  The UV absorbance was recorded at 240 
nm. WT- TTR concentration in serum was measured using nephelometric analyzer (28 mg/dL or 
5 µM). 
Chemical synthesis of AG10 analogues (Scheme 1). Methyl 3-(3-(3,5-dimethyl-1H-
pyrazol-4-yl)propoxy)-4-fluorobenzoate (1):  A solution of methyl 3-(3-bromopropoxy)-4-
fluorobenzoate (4) [3] (780 mg, 2.69 mmol, 1 equiv) in benzene (3 ml) was added dropwise to a 
solution of acetyl acetone (0.552 ml, 5.38 mmol, 2 equiv) and DBU (0.804 ml, 5.38 mmol, 2 
equiv) in benzene (7 ml).  The reaction mixture was stirred at room temperature for 3 days.  The 
mixture was filtered and concentrated.  The residue was purified by flash column 
chromatography (silica gel, 1-10% EtOAc/hexanes) to afford the alkylated intermediate which 
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was used in the next step directly.  To a solution of this intermediate in ethanol (5 ml) was added 
hydrazine hydrate (0.36 ml, 6.73 mmol, 2.5 equiv) and the reaction was heated under reflux for 4 
hr.  The reaction was concentrated and purified by flash column chromatography (silica gel, 1-
20% MeOH/CH2Cl2) to afford compound 1 (288 mg, 35% yield); (96.3% purity by HPLC): tR 
(column) (C18) = 25.1 min; tR (C4) = 14.0 min.  1H NMR (CD3OD, 600 MHz) δ 7.63-7.58 (m, 
2H), 7.19-7.15 (m, 1H), 4.00 (t, 2H, J = 6.0 Hz), 3.86 (s, 3H), 2.58 (t, 2H, J = 7.2 Hz), 2.12 (s, 
6H), 1.97-1.92 (m, 2H). 13C NMR (CD3OD, 600 MHz) δ 168.1, 158.4, 156.7, 148.9, 128.5, 
124.6, 117.6, 117.0, 115.6, 69.4, 53.3, 31.1, 20.2, 10.9; HRMS (DART) m/z: calcd for 
C16H19FN2O3 + H+ 307.1458; found 307.1463 (M+H+). 
4-fluoro-3-(3-(1,3,5-trimethyl-1H-pyrazol-4-yl)propoxy)benzoic acid (2): A solution of 1 (21 
mg, 0.07 mmol, 1 equiv) in DMF (3 ml) was added sodium hydride (5 mg, 0.21 mmol, 3 equiv) 
and methyl iodide (17 µl, 0.28 mmol, 4 equiv).  The reaction mixture was stirred at room 
temperature for 2 hr. The mixture was extracted with brine, filtered and concentrated.  The 
residue was purified by flash column chromatography (silica gel, 0.5-2% MeOH/EtOAc) to 
afford the alkylated intermediate which was used in the next step directly.  Sodium hydroxide 
(5.6 mg, 0.14 mmol, 2 equiv) in water (0.5 ml) was added to a solution of alkylated intermediate 
in methanol (2 ml) and the reaction was heated under reflux for 4 hr (50°C).  The reaction was 
concentrated and purified by flash column chromatography (silica gel, 1-5% MeOH/EtOAc) to 
afford compound 2 (11 mg, 52% yield for two steps); (97.8% purity by HPLC): tR (column) 
(C18) = 25.3 min; tR (C4) = 15.7 min. 1H NMR (CD3OD, 600 MHz) δ 7.58-7.51 (m, 2H), 7.10-
7.06 (m, 1H), 3.92 (t, 2H, J = 6.0 Hz), 3.56 (s, 3H), 2.49 (t, 2H, J = 7.2 Hz), 2.05 (s, 3H), 2.01 (s, 
3H), 1.83-1.88 (m, 2H). 13C NMR (CD3OD, 600 MHz) δ 168.1, 154.6, 146.8, 145.3, 137.2, 
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128.1, 122.8, 115.5, 115.4, 114.8, 67.4, 34.3, 29.4, 18.8, 10.1, 7.9; HRMS (DART) m/z: calcd 
for C16H19FN2O3 + H+ 307.1458; found 307.1449 (M+H+). 
Methyl 3-(3-(3,5-diethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoate (5): A solution of 4 
(100 mg, 0.35 mmol, 1 equiv) in benzene (2 ml) was added dropwise to a solution of 3,5-
heptanedione (0.095 ml, 0.7 mmol, 2 equiv) and DBU (0.104 ml, 0.7 mmol, 2 equiv) in benzene 
(5 ml).  The reaction mixture was stirred at room temperature for 3 days.  The mixture was 
filtered and concentrated.  The residue was purified by flash column chromatography (silica gel, 
1-10% EtOAc/hexanes) to afford the alkylated intermediate which was used in the next step 
directly.  Hydrazine hydrate (0.047ml, 0.875 mmol, 2.5 equiv) was added to the alkylated 
intermediate in ethanol (4 ml) and the reaction was heated under reflux for 4 hr.  The reaction 
was concentrated and purified by flash column chromatography (silica gel, 1-5% MeOH/EtOAc) 
to afford compound 5 (75 mg, 65% yield for two steps); 1 H NMR (CD3OD, 600 MHz) δ 7.59-
7.54 (m, 2H), 7.15-7.11 (m, 1H), 3.98 (t, 2H, J = 6.0 Hz), 3.81 (s, 3H), 2.56-2.47 (m, 6H), 1.91-
1.86 (m, 2H), 1.13 (t, 6H, J=7.8 Hz). 13C NMR (CD3OD, 600 MHz) δ 167.9, 156.6, 156.2, 148.8, 
148.7, 124.4, 117.5, 117.3, 116.9, 113.9, 69.5, 53.1, 31.8, 20.1, 14.7; HRMS (DART) m/z: calcd 
for C18H23FN2O3 + H+ 335.1771; found 335.1773 (M+H+). 
3-(3-(3,5-diethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid (3): Sodium hydroxide (3.2 
mg, 0.08 mmol, 2 equiv) in water (0.5 ml) was added to a solution of 5 (13 mg, 0.04 mmol, 1 
equiv) in methanol (2 ml) and the reaction was heated under reflux for 4 hr (50°C).  The reaction 
was concentrated and purified by flash column chromatography (silica gel, 1-5% MeOH/EtOAc) 
to afford compound 3 (10 mg, 80% yield); (96.0% purity by HPLC): tR (column) (C18) = 25.2 
min; tR (C4) = 15.5 min. 1H NMR (CD3OD, 600 MHz) δ 7.57-7.49 (m, 2H), 7.08-7.04 (m, 1H), 
3.94 (t, 2H, J = 6.0 Hz), 2.51-2.43 (m, 6H), 1.87-1.82 (m, 2H), 1.06 (t, 6H, J=7.8 Hz). 13C NMR 
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(CD3OD, 600 MHz) δ 169.8, 157.9, 156.3, 149.3, 148.5, 124.6, 117.2, 117.1, 114.1, 69.4, 31.8, 
20.1, 19.9, 14.7; HRMS (DART) m/z: calcd for C17H21FN2O3 + H+ 321.1614; found 321.1601 
(M+H+). 
HPLC method for analysis of the purity of AG10 analogues.  The analysis was performed 
on Agilent 1100 series HPLC system connected to a diode array detector operating between the 
UV ranges of 200 – 400 nm and quantified using Agilent Chemstation software.  The HPLC 
analysis was performed on both Waters™ XBridge C18 column with L1 packing (4.6 X 250 
mm, 5μm) and SymmetricTM C4 (2.1 X 150 mm, 5μm) at ambient temperature upon injection of 
a 50 μl of each Blank buffer, standard and/or sample to obtain the chromatogram.  The mobile 
phase was composed of solvent A consisting methanol-water (5:95, v/v) containing 0.1 % formic 
acid and solvent B consisting methanol-water (95:5, v/v) containing 0.1 % formic acid.  The 
HPLC program was a gradient separation method increasing linearly from 0 % to 100 % solvent 
B from 0 to 20 min or 30 min. 
Chemical synthesis of covalent probe-3.  (E)-S-phenyl 3-(4-hydroxy-3,5-
dimethylstyryl)benzothioate (Covalent probe 3): synthesized as reported earlier [57].  1H NMR 
(DMSO-d6, 600 MHz) δ 8.44 (s, 1H), 8.03 (m, 1H), 7.90 (d, 1H, J = 7.7 Hz), 7.78 (d, 1H, J = 7.7 
Hz), 7.55-7.48 (m, 6H), 7.22-7.10 (m, 4H), 2.16 (s, 6H); HRMS (DART) m/z calcd for 
C14H7Cl2NO3 + H+ 361.1257; found 361.1260 (M + H+). 
Competition fluorescence polarization (FP) assay for binding to TTR in buffer.  The 
affinity of test compounds to TTR was determined by their ability to displace FP probe from 
TTR using our recently developed FP assay [75].  The apparent binding constant (Kapp) was 
reported as the mean for triplicate experiments and the best data fit was determined by R2 value.  
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The Kapp values were calculated by the modified Cheng-Prusoff equation 
(Kapp=IC50/(1+([competitor]/competitor Kd)) from IC50 values obtained by four parameter 
variable slope fit using the equation: Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-
X)*HillSlope)). Serial dilutions of AG10 and its analogues (0.003 µM to 100 µM) were added to 
a solution of FP-probe and TTR in assay buffer (25 µL final volume). 
Fluorescence probe exclusion (FPE) assay for ligand binding affinity and selectivity to 
TTR in human and dog serum.  The binding affinity and selectivity of test compounds to TTR 
was determined by their ability to compete for FPE probe binding to TTR in human serum as 
previously reported [57, 68].  The FPE probe is not fluorescent by itself, however upon binding 
to TTR it covalently modifies the ε-amino group of the K15 amino acid residue within the T4 
binding pocket, creating an amide-linked fluorescent conjugate.  We also adapted the FPE assay 
for use with dog serum.  An aliquot of 98 µL of pooled human serum (prepared from human 
male AB plasma, Sigma, catalog no.: H4522) or dog serum (Innovative Research, catalog no.: 
IBG-SER) was mixed with 1 µL of test compounds (1.0 mM stock solution in DMSO, final 
concentration: 10 µM) and 1 µL of FPE probe (0.36 mM stock solution in DMSO: final 
concentration: 3.6 µM).  In the case of dog serum (after oral treatment with AG10), 1 µL of FPE 
probe and 1 µL of DMSO were added to each well and mixed with 98 µL of the appropriate dog 
serum sample.  The fluorescence changes (λex = 328 nm and λem = 384 nm) were monitored 
every 15 min using a microplate spectrophotometer reader (Molecular Devices SpectraMax M5) 
for 6 hr at room temperature. 
Stability studies of TTR in serum by immunoblotting. Western Blotting was performed as 
previously published [3, 49].  All compounds were prepared as 10 mM stock solutions in DMSO 
and diluted accordingly with DMSO (final concentrations were: AG10 10 µM; tafamidis 20 µM; 
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tolcapone 20 µM; diflunisal 200 µM).  2 μL of each compound was added to 98 μL of human 
serum (from human male AB plasma, Sigma; catalog no. H4522) (TTR concentration ∼5 μM).  
The samples were incubated at 37°C for 2 hr, and then 10 μL of the samples were diluted 1:10 
with acidification buffer (pH 4.0, 100 mM sodium acetate, 100 mM KCl, 1 mM EDTA, 1 mM 
DTT).  The samples were incubated at room temperature for 72 hr and then cross-linked with 
glutaraldehyde (final concentration of 2.5%) for 5 min, and then quenched with 10 μL of 7% 
sodium borohydride solution in 0.1 M NaOH.  All samples were denatured by adding 100 μL 
SDS gel loading buffer and boiled for 5 min.  10 μL of each sample was separated in 12% SDS-
PAGE gel and analyzed by immunoblotting using anti-TTR antiserum (DAKO A0002, 1:10,000 
dilution for human serum and 1:2,000 for dog serum).  The combined intensity of TTR bands 
(TTR tetramer and TTR bound to RBP) was quantified by using an Odyssey IR imaging system 
(LI-COR Bioscience) and reported as percentage of TTR tetramer, calculated as 100 × [(tetramer 
and tetramer + RBP density, 72 hr)/(tetramer and tetramer + RBP density of DMSO, 0 hr)].  
In silico structural and modeling studies.  The analyses of the crystal structures of TTR 
were carried out on four TTR crystal structures obtained from the RCSB PDB site [76].  An apo 
form of human TTRwt (pdb id: 3CFM) [65], T119M mutant (pdb id: 1FHN) [62], and R104H 
mutant (pdb id: 1X7T) [64] structures were compared with the V122I mutant TTR in complex 
with AG10 (pdb id: 4HIQ) [3] and V122I mutant TTR in complex with tafamidis (pdb id: 
4HIS)[3].  UCSF Chimera package [77] was used in visualization and analyses of the 3D 
structures.  Biological assemblies of TTR tetramers were constructed using the X-ray 
crystallographic unit cell information given in the pdb files.  When multiple models are 
suggested, the first choice model was used.  
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The initial geometries of the AG10 and its three derivatives (1, 2, and 3) built with Molden 
[78] were used and geometry optimizations were carried out at the hybrid density functional 
B3LYP [79] level with 6-311+G(d) [80] basis set using Gaussian’09 program package [81].  The 
Frequency calculations on the optimized geometries were carried out to ensure they have no 
imaginary frequencies.  Dock 6 program was used for the docking experiments [82].  The crystal 
structure of the V122I mutant TTR complex with AG10 (pdb id: 4HIQ [3]) was used as the 
receptor.  Tetrameric TTR was built using the crystallographic data, solvent and other hetero-
atoms were removed and one large docking grid was selected including the T4 binding pockets.  
For all the docking experiments, the same receptor and the grid were used.  The flexible ligand 
docking was carried out to allow the rotation around the torsion angles.  The docking results are 
visualized and analyzed using UCSF Chimera [77].   
Binding of AG10 and tafamidis to human serum albumin.  Test compounds (AG10 or 
tafamidis; both at 30 µM) were incubated with human serum albumin (HSA; 600 µM; albumin 
from human serum; Sigma Aldrich, catalog no.: A3782) in assay buffer (10 mM sodium 
phosphate, 100 mM KCl, and 1 mM EDTA, pH 7.6) for 1 hr at 37oC.  500 µL of a solution of 
HSA and AG10 or tafamidis mixture in assay buffer was subjected to gel filtration on PD 
Minitrap G25 columns (GE Life Sciences, catalog no. 45-001- 529) by gravity and the fractions 
containing HSA were identified by NanoDrop™.  The concentration of HSA (i.e. conc. at time 
zero) was also determined using NanoDrop™ (based on calibration curves of known HSA 
concentrations).  HSA concentration was ~351 µM for the tafamidis sample and ~345 µM for 
AG10 sample.  The concentration of test compounds in these fractions (i.e. conc. at time zero) 
was evaluated using HPLC (based on calibration curves of known concentration of test 
compounds).  500 µL of each HSA/test compound samples was then added to a Slide-A-Lyzer 
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Dialysis Cassette G2 (Thermo Scientific, catalog no. PI87722).  The dialysis Cassettes were 
placed in 100 ml of assay buffer and stirred at room temperature.  After 24 hr, the samples were 
removed from dialysis cassette and the volume was measured.  The concentration of HSA and 
test compounds were determined using NanoDrop™ and HPLC as described above. 
Dialysis of AG10:TTR complex.  AG10 (10 µM) was incubated with human TTRwt (5 µM; 
purified from human plasma; Sigma Aldrich, catalog no. P1742) in assay buffer (10 mM sodium 
phosphate, 100 mM KCl, and 1 mM EDTA, pH 7.6) for 1 hr at 37oC.  500 µL of each 
AG10/TTR solution was then added to a Slide-A-Lyzer Dialysis cassette G2 (Thermo Scientific, 
catalog no. PI87722) (3.5K MWCO).  The dialysis cassettes were placed in 100 mL of assay 
buffer and stirred at room temperature.  Samples from the dialysis buffer were taken at different 
time points (0, 0.5, 1, 2, 6, and 24 hr).  After 24 hr, the samples were removed from dialysis 
cassette and the volume was measured and results normalized.  The concentration of TTR and 
AG10 obtained from the assay buffer were determined using NanoDrop™ and HPLC, 
respectively. 
Selectivity of AG10 to TTR compared to other serum proteins.  The FPE assay was 
modified and performed with purified human TTRwt (5 µM).  Other serum proteins were added 
either individually or in combination [fibrinogen (5 µM), albumin (600 µM), IgG (70 µM), 
transferrin (25 µM)] to the TTR and FPE mixture and the fluorescence was monitored for 6 hr as 
described above.  The percentage of FPE probe binding to TTR in the presence of serum proteins 
measured after 3 hr of incubation was used to calculate % TTR occupancy.  
Determination of TTR concentration in dog serum.  The concentration of TTR in 
commercially available beagle dog serum (Innovative Research, catalog number: IBG-COMPL) 
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was determined using a commercially available canine prealbumin (PA) ELISA Kit (Lifeome 
BioLabs, catalog number: CSB-E13252c). The assay was performed per the instructions of 
ELISA kit manufacturer.   
7-day repeat oral dosing of AG10 to dogs.  Male and female beagle dogs, separated into 
four treatment groups and dosed with vehicle (6M/6F at 0 mg/kg) or AG10 in 0.5% 
methylcellulose formulation (2M/2F at 50 mg/kg, 2M/2F at 100 mg/kg, and 6M/6F at 200 
mg/kg) for a total of 32 dogs.  Blood (approximately 1.5 mL) was collected from a jugular vein 
into serum separator tubes on study day 1 (predose D1), pre-dose study day 7 (predose D7), and 
at 1 hr post-dose study day 7 (postdose D7).  These serum samples were analyzed for their TTR 
occupancy using the FPE assay described above.  *Analysis performed by Arindom Pal of Dr. 
Alhamadsheh group. 
Single oral dose of AG10 to dogs to determine an exposure-effect (PK-PD) relationship 
with respect to binding to and stabilization of TTR.  Male and female beagle dogs, separated 
into two treatment groups (n=2/sex/group) for a total of 8 dogs were evaluated to acquire 
simultaneous pharmacokinetic (PK) and pharmacodynamic (PD) data for AG10 binding to and 
stabilization of TTR.  Each animal received a single oral gavage (PO) of AG10 at a single dose 
of either 5 or 20mg/kg in 0.5% methylcellulose.  Blood was collected and analyzed pre-dose and 
at 2, 4, 6, 8, 12 and 24 hr post-dose.  The concentration of AG10 in these serum samples was 
analyzed by LCMS and the TTR occupancy by the FPE assay.  
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Chapter 3: Harnessing Transthyretin to Extend the In Vivo Half-Life of Peptides 
3.1 Introduction 
Therapeutic peptides are used for a range of disorders, such as cancer, diabetes, and others 
[83, 84].  Due to their higher potency, selectivity, and safety over small molecules, the number of 
new peptides entering clinical trials continues to grow.  In addition, peptides hold great potential 
as both diagnostic agents and targeting ligands [85, 86].  Unfortunately, most peptides have short 
in vivo half-life (t1/2 of 2–30 minutes) due to enzymatic degradation by proteases and fast renal 
clearance (molecules <30 kD are excreted rapidly by glomerular filtration).  Therefore, extending 
the in vivo t1/2 of peptides is clear strategy in order for their therapeutic potential to be realized 
without the need for high doses and frequent administration.  
Conjugation of proteins to polyethylene glycol (PEG) (~20–40 kDa) has proven to be an 
effective strategy for extending their in vivo t1/2 [87].  However, due to its non-biodegradable 
nature, repeated administration of some PEGylated proteins has been associated with cellular 
toxicity and generation of anti-PEG antibodies [88, 89].  The chemical conjugation process and 
heterogeneity of PEG typically yields complex product mixtures.
Genetic fusion of proteins to unstructured proteins [90], antibody Fc domains, and human 
serum albumin (HSA; 67 kDa) offer an alternative approach to PEGylation [87].  While 
conjugation to macromolecules is a successful strategy with many proteins, their use with 
peptides is limited [91, 92].  The steric hindrance of macromolecules is especially detrimental to 
the activity of short peptides (<30 amino acid) where the peptide binding epitope is in close 
proximity to the macromolecule.   Several reversible albumin binding peptides [93-95] and small 
molecules [96, 97] are successful in enhancing the in vivo t1/2 of proteins.  However, due to the 
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high affinity of these ligands to HSA, combined with the molar abundance of HSA (600 µM, 60 
% of the total plasma protein pool), these albumin tags show limited success in maintaining 
peptides’ potency in vivo [96, 98].  Covalent conjugation of peptides to macromolecules such as 
PEG and HSA enhances the in vivo t1/2 of peptides by sterically protecting the peptide from 
proteases and by increasing the hydrodynamic size of the peptide and therefore decreasing its 
renal excretion.  However, the steric hindrance of macromolecules often harms the binding 
affinity of peptides to its extra-cellular receptor, which compromises the therapeutic potency of 
peptides.  While extended t1/2 is desirable in certain chronic conditions (e.g. t1/2 of few days for 
albumin—GLP-1 conjugates for Type II diabetes), sometimes it is undesirable to maintain 
therapeutic agents in circulation for prolonged periods.  Peptides with intermediate t1/2 (few 
hours) are preferred in certain applications, such as diagnostic agents (e.g. 111Indium 
radiolabeled—Octreotide for imaging of neuroendocrine tumors) [99] and certain peptide 
hormones where prolonged exposure can cause serious side effects (e.g. Carbetocin, an obstetric 
drug used to control postpartum hemorrhage) [100].  Thus, strategies that enhance the in vivo t1/2 
of peptides while maintaining their potency are still greatly sought.  
Transthyretin (TTR) is a 55 kDa homo-tetramer that is secreted from liver into blood and has 
in vivo t1/2 of ~48 h (Figure 3.1) [101].  The main function of TTR in human (hTTR; conc. ~5 
µM) is to transport holo-retinol binding protein (RBP bound to retinol, or vitamin A) in blood.  
The apo-RBP (RBP without retinol) has low affinity for hTTR and therefore, due to its relatively 
small size (21 kDa), undergoes fast renal excretion (t1/2 ~3.5 h) [101].  Reversible association 
between holo-RBP and hTTR in blood (holo-RBP-TTR complex; ~76 kDa) decreases 
glomerular filtration of holo-RBP which results in 3-fold increase in circulation t1/2 (~11 h).  
Inspired by this natural observation, we hypothesized that conjugation of peptides to selective 
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small molecule hTTR-binding ligands will allow the peptide conjugates to bind reversibly to 
circulating endogenous hTTR and increase their in vivo t1/2.  Importantly, due to their reversible 
binding to hTTR, the intrinsic activity of the peptide conjugates would not be adversely affected 
(Figure 3.2).  Using orthogonal sites to those of holo-RBP, hTTR acts as a back-up carrier of 
thyroxine (T4) (<1 % T4 bound) [28].  We developed a high-throughput screening assay that can 
detect binding of small molecules to the T4 binding pocket of hTTR [56].  Recently, our group 
developed a very potent and selective small-molecule hTTR ligand (AG10; Figure 3.1) [3].  At 
10 µM, almost all of AG10 is bound to hTTR in human serum (1:1 binding, based on hTTR 
serum concentration of 5 µM and two binding sites) [3].  Using insights from our crystal 
structure of AG10-bound to hTTR [3], we successfully developed linker-modified AG10 analogs 
that we term TTR ligands for half-life extension, TLHEs.  This will increase the in vivo t1/2 of 
peptides by protecting against proteases and by decreasing glomerular filtration.  Importantly, 
due to its reversible binding to hTTR, the binding affinity of the peptide conjugate to its target 
receptor would not be adversely affected.  Here we have demonstrated that conjugation of a 
TLHE to a model peptide did enhance the in vivo t1/2 of the peptide without compromising its 
target affinity, which was translated into superior in vivo efficacy.  These findings show that our 
approach has potential to greatly expand the scope of research and therapeutic applications of 
peptides. 
This work, previously presented by my former labmate, Dr. Sravan Penchala, was done in 
cooperation (as indicated by our co-authored paper, published in the journal, Nature Chemical 
Biology [102]). 
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Figure 3.1 Crystal structure of hTTR bound to AG10 with monomers colored individually and a 
box showing close-up view of AG10 bound in one of the two hTTR T4 pockets (PDBID: 4HIQ) 
[4]. 
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Figure 3.2 Current approaches for enhancing the in vivo t1/2 of peptides and our new hTTR based 
approach. (a) Most peptides have short in vivo t1/2 (2–30 minutes) due to enzymatic degradation 
by proteases and fast renal excretion by glomerular filtration. (b) Covalent conjugation of 
peptides to macromolecules such as PEG and HSA enhances the in vivo t1/2 of peptides by 
sterically protecting the peptide from proteases and by increasing the hydrodynamic size of the 
peptide and therefore decreasing its renal excretion. (c) Conjugation of peptides to TTR ligands 
for half-life extension (TLHEs) (<500 Da), through a short linker will give TLHE—peptide 
conjugates. (d) The TLHE—peptide conjugate can bind reversibly to the T4 binding sites of 
endogenous hTTR (shown as ribbon diagram with transparent surface) [102].   
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3.2 Results 
Development of AG10–linkers (TLHEs) for conjugation to peptides.  Removing the 
fluorine atom of AG10 resulted in analog 2 which maintained similar binding affinity and 
selectivity to hTTR.  Therefore, a short linker equipped with a terminal alkyne was attached to 2 
to generate TLHE1 (3) (Figure 3.5).  To test our hypothesis, we conjugated TLHE1 to four 
different peptides to give fourTLHE1—peptide conjugates; 5, 6, 7, 8 (Figure 3.5).  Compound 5 
is TLHE1 conjugated to the fluorogenic tripeptide Arg-Gly-Lys-MCA.  Stability of 5 was 
evaluated in the in vitro trypsin assay in the presence of hTTR.  Compound 6 is conjugated 
through TLHE1 to the N-terminus of neurotensin (NT).  Stability of 6 was evaluated in the 
human serum protease assay. Compound 7 is TLHE1 conjugated to the N-terminus of native 
GnRH.  Stability of 7 was evaluated in the human serum protease assay and its pharmacokinetic 
properties were evaluated in vivo in rats.  Compound 8 is TLHE1 conjugated to the ε-amino 
group of Lys6 in the GnRH agonist, GnRH-A. Pharmacokinetic properties and efficacy of 8 were 
evaluated in vivo in rats. 
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Figure 3.3 Chemical structure of TLHE1 and four TLHE1-peptide conjugates.  *Peptide and 
organic synthesis was a collaborative effort with Dr. Sravan Penchala with specific focus given 
to TLHE1 and conjugate 6 and 7 by me.   
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Conjugates 7 and 8 binds to TTR with high binding affinity.  We used SPR to study the 
binding affinity of 7 and 8 to TTR which exhibited concentration dependent binding to TTR (Kd 
= 317 ± 5 nM and Kd = 380 ± 5 nM, respectively; Figure 3.8) and displayed favorable binding 
kinetics with rapid on-rate and a slow off-rate (kon = 6.36 × 104 M−1 s−1, koff = 0.0202 s−1 and kon 
= 3.93 × 104 M−1 s−1, koff = 0.0149 s−1, respectively; Figure 3.8).  *SPR studies on conjugate 7 
performed by me, while conjugate performed by Dr. Sravan Penchala. 
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Figure 3.4 Assessment of the binding affinity of 7 and 8 to TTR using SPR.  SPR sensograms 
showing concentration-dependent binding of (a) 7 (conc. 30 to 1920 nM; Kd = 380 ± 5 nM) and 
(b) 8 (conc. 30 to 1920 nM; Kd = 317 ± 5 nM) to TTR immobilized on the sensor chip.  
Normalized µRiUs are plotted over a time course.  *Conjugate 8 performed by Dr. Sravan 
Penchala. 
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TLHE1 and peptide conjugates binds selectively to WT-TTR in human serum.  The 
selectivity of TLHE1 to hTTR in human serum was evaluated using a well-established hTTR 
serum FPE assay as shown in Figure 3.9 and 3.10 [3, 57].  The lower performance of TLHE1 (70 
% binding to hTTR in serum) compared to AG10 (Kd = 4.8 nM; 98 % binding to hTTR in serum) 
was due to the 10-fold lower binding affinity of TLHE1 and possibly some binding to other 
serum proteins.  Nevertheless, the activity of TLHE1 in this assay was better than that of the 
clinical candidate, tafamidis (45 % binding to hTTR in serum).  All four conjugates (5, 6, 7 and 
8) displayed high binding affinity and selectivity for hTTR in human serum (~46 to 57 % 
binding to hTTR in human serum; Figure 3.9 and Table 3.1). 
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Figure 3.5 Fluorescence change caused by modification of hTTR in human serum (hTTR 
concentration, ~5 μM) by covalent probe monitored for 6 h in the presence of covalent probe 
alone (black circles) or covalent probe and hTTR ligands (colors; 10 μM).  The lower the binding 
and fluorescence of covalent probe, the higher binding selectivity of ligand to hTTR.  Each bar 
shows the mean ± SD of three replicates.  *Performed by Dr. Sravan Penchala; initial FPE 
studies of conjugate 6 and 7 performed by me.  
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Figure 3.6 Binding selectivity of ligands to hTTR in human serum.  (a) Chemical structure of 
covalent-probe.  (b) Percentage of covalent-probe binding to hTTR in the presence of ligands (10 
µM) measured after 3 h of incubation relative to covalent-probe alone.  The lower the binding 
and fluorescence of covalent-probe, the higher binding selectivity of ligand to hTTR.  Each bar 
shows the mean (± SD) of three replicates. 
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Table 3.1 Summary of binding affinity and selectivity of ligands to hTTR in buffer and human 
serum.  Binding affinity (Kd in nM) of ligands to hTTR in buffer was determined using SPR. 
Selectivity of ligands to hTTR in human serum was evaluated using covalent-probe assay.  The 
% covalent-probe fluorescence in the presence of ligands (10 µM) at 3 h (Figure 3.9 and 3.10) 
was used to estimate the % of ligand bound to hTTR in human serum. 
 
  
Compound 
Kd for hTTR in buffer 
determined by SPR 
% binding to hTTR in human 
serum 
AG10 4.8 nM 98 ± 0.3 
Tafamidis 4.4 nM 45 ± 1.1 
2 22 nM 95 ± 0.2 
TLHE1 42 nM 70 ± 0.5 
5 172 nM 52 ± 0.2 
6 460 nM 46 ± 1.9 
7 380 nM 54 ± 0.1 
8 317 nM 57 ± 0.9 
NT—Linker  > 10,000 nM 0 
GnRH—Linker  > 10,000 nM 0 
GnRH-A—Linker  > 10,000 nM 0 
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hTTR protected 6 and 7 against serum proteases.  The stability of 6 and 7 was evaluated 
in human serum (hTTR conc. ~5 µM) and in serum samples that are pre-incubated with AG10.  
As expected, NT and GnRH had the lowest stability in serum (no detectable amounts of NT and 
GnRH after 4 h and 2 h, respectively; Figure 3.13).  Attaching a short linker to NT (NT—Linker) 
and GnRH (GnRH—Linker) enhanced their stability (38 ± 2% of NT—Linker remaining at 4 h 
and 85 ± 4% of GnRH—Linker remaining at 2 h).  In comparison, 6 (22 ± 1% remaining at 48 h) 
and 7 (58 ± 4% remaining at 48 h) showed the most protection against serum proteases.  As 
expected, there was no difference in NT—Linker and GnRH—Linker stability between normal 
serum and serum incubated with AG10.  On the other hand, the stability of 6 and 7 in normal 
serum was higher than that in serum samples pre-incubated with AG10 (no detectable amount of 
6 and 7 after 24 h and 48 h, respectively). 
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Figure 3.7 hTTR protected 6 (a) and 7 (b) against proteolytic hydrolysis in human serum (hTTR 
concentration ~5 μM).  Test compounds (5 μM) were added to serum and to serum preincubated 
with AG10 (10 μM).  The amounts of compounds remaining in serum were quantitated at 
indicated time points.  Each point shows the mean ± SD of three replicates.  *Animal PK studies 
performed with the supervision of Dr. Miki Park by Dr. Sravan Penchala with assistance by me.  
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TTR extended the circulation t1/2 of 7 in rats.  Pharmacokinetic evaluation was performed 
by injecting equivalent amounts of GnRH, GnRH—Linker and 7 were administered as a single 
i.v. bolus to a group of male rats and the plasma concentrations of test compounds were 
measured at different time points (Figure 3.14).  For control, another set of rats was co-
administered with same test compounds (GnRH, GnRH—Linker, and 7) but in the presence of 
AG10.  The results indicate that there was no measurable amount of GnRH at 15 min after 
administration, which is consistent with the reported short in vivo t1/2 (Figure 3.14).  The t1/2 of 
GnRH—Linker was similar in AG10-treated and untreated rats (t1/2 = 4.2 min & 3.5 min, 
respectively; Figure 3.15).  In contrast, 7 displayed initial rapid distribution phase (t1/2 = 12 min) 
followed by a longer terminal t1/2 (46 ± 3 min).  The terminal t1/2 of 7 is at least 13-fold longer 
than that of GnRH or GnRH—Linker (Figure 3.14).  
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Figure 3.8 Evaluating the pharmacokinetic profile of 7 in rats.  The concentration of test 
compounds in plasma was determined using a validated HPLC method and plotted as a function 
of time after dosing.  Concentrations are expressed as mean ± SEM of four biological replicates.  
*Animal PK studies performed with the supervision of Dr. Miki Park by Dr. Sravan Penchala 
with assistance by me. 
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Effect of 8 on holo-RBP-TTR interaction.  In an effort to rule out the possibility that 8 
would interfere with the holo-RBP binding to TTR, we studied the interaction between holo-
RBP-TTR in buffer using SPR (Figure 3.18).  The interaction of 8 and holo-RBP (4 μM and 0.2 
μM, respectively; 74 ± 1 μRiU) with hTTR on sensor chip is almost a combination of individual 
responses to 8 (4 μM; 34 ± 0.1 μRiU) and holo-RBP (0.2 μM; 46 ± 0.1 μRiU).  Our results 
confirmed data reported in literature for that TTR can indeed interact with both 8 and holo-RBP 
in concert. 
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Figure 3.9 SPR sensogram showing that interaction of 8 and holo-RBP.  Normalized μRiUs are 
plotted over time.  The sensogram is a representation of a duplicate experiment. *Performed in 
collaboration with Dr. Sravan Penchala. 
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rTTR extended the circulation t1/2 of 8 in rats.  The pharmacokinetic properties of GnRH-
A, GnRH-A—Linker, and 8 were evaluated in rats, in the absence and presence of AG10 (Figure 
3.19).  The t1/2 of GnRH-A was 55 ± 11 min and there was no detectable levels in plasma after 2 
h of administration.  As expected, similar t1/2 for GnRH-A was observed in AG10-treated rats 
(t1/2 = 49 ± 4 min).  The PK profile and t1/2 of GnRH-A—Linker (t1/2 = 58 ± 7 min) was 
comparable to that of GnRH-A, and there were no detectable levels of GnRH-A—Linker after 2 
h in both AG10-treated and untreated rats (Figure 3.20).  These data were expected because both 
compounds are small in size (<1.5 kDa), therefore are quickly excreted by glomerular filtration.  
In comparison, 8 displayed initial rapid distribution phase (t1/2 = 14 min) followed by a much 
longer terminal t1/2 (180 ± 12 min) which is >3-fold longer than the t1/2 of GnRH-A.  While there 
were no detectable plasma levels of GnRH-A after 2 h, 8 was present in circulation for at least 12 
h (Figure 3.19).  As expected, the t1/2 of 8 in AG10-treated rats (t1/2 = 102 ± 7 min) was 
significantly lower than that in AG10-untreated rats.  
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Figure 3.10 Evaluation of the pharmacokinetic properties of 8 in rats.  The concentration of test 
compounds in plasma was determined using validated HPLC method and plotted as a function of 
time after dosing.  Concentrations are expressed as means ± SEM of three biological replicates.  
*Animal PK studies performed with the supervision of Dr. Miki Park by Dr. Sravan Penchala 
with assistance by me. 
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Binding to rTTR enhanced the GnRH-R efficacy of 8 in rats.  Acute dosing of exogenous 
GnRH agonists is known to cause prompt increase in testosterone levels in male rats [107].  
Therefore, the in vivo efficacy of 8 on circulating levels of testosterone was evaluated in male 
rats.  8, GnRH-A, or vehicle were administered to three groups of rats, and the serum 
concentration of testosterone was determined at various time points (Figure 3.21).  In vehicle 
treated rats, a normal circadian rhythm of testosterone was observed (normal range of serum 
testosterone in rat is 0.7–5 ng/ml).  Administration of equivalent doses of GnRH-A or 8 resulted 
in significant increase of testosterone levels within 1 h after injection (35.8 ± 1.7 ng/ml and 35.6 
± 3.2 ng/ml, respectively; Figure 3.21).  While testosterone levels in both treated groups started 
decreasing after 1 h, the decline in GnRH-A treated rats was significantly faster than that for 8 
treated rats.  At 6 h, there was a significant difference in testosterone levels between rats treated 
with GnRH-A (13.2 ± 1.3 ng/ml) and 8 (25.6 ± 2.8 ng/ml).  For GnRH-A, the circulating 
testosterone levels returned to vehicle treated levels (3.6 ± 0.6 ng/ml) within 8 h after dosing.  In 
contrast, the testosterone levels in rats treated with 8 at 8 h (18.9 ± 1.0 ng/ml) were significantly 
higher compared to that of rats treated with GnRH-A or vehicle.  Importantly, the testosterone 
level for rats treated with 8 was still elevated at 12 h post dosing (12.7 ± 2.3 ng/ml) compared to 
vehicle treated rats (0.8 ± 0.3 ng/ml) (increase of ~16 fold above basal levels).  The circulating 
testosterone levels of 8 treated rats returned to the pretreatment range within 24 h.  
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Figure 3.11 Evaluating the efficacy of 8 in rats.  Testosterone levels in serum were determined 
using ELISA, and concentrations were expressed as means ± SEM of four biological replicates.  
*P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. 
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3.3 Discussion 
We found that the in vitro microsomal stability of AG10 is enhanced in the presence of hTTR 
(Figure 3.3) [102].  In addition, intravenous administration of increasing doses of AG10 to rats 
displayed a biphasic pharmacokinetic profile with extended terminal t1/2 (terminal t1/2 = 550 min) 
which is a characteristic of target-mediated drug disposition (TMDD).  These experiments 
indicated that the extended in vivo t1/2 of AG10 is mainly due to its binding to rTTR in rat 
plasma.  Moreover, AG10 is orally bioavailable and lacks toxicity in rodents, which make it a 
very promising compound to be used for designing ligands that can harness the bulk of hTTR in 
blood [3].  Hence, we attached a linker to AG10 to generate TLHEs and the best linker is 
TLHE1. 
Our modeling studies suggested that extending the linker of TLHE1 to a length of ~20 Å 
(Figure 3.22) should be sufficient to clear out of the hTTR T4 binding sites and potentially be 
functionalized with peptides [102].  For our approach to work in vivo, TLHE1 and its peptide 
conjugates should be able to selectively bind to hTTR in the presence of more than 4,000 other 
human serum proteins.  Our covalent-probe selectivity assay results showed that TLHE1 and the 
peptide conjugates (5, 6, 7 and 8) displayed good selectivity for hTTR in human serum (~46 to 
57 % binding to hTTR in human serum; Figure 3.9 and Table 3.1).  Similar to AG10 [3], TLHE1 
was stable in serum and simulated gastric acid for at least 48 h (<3 % degradation; Figure 3.11) 
and has very low cytotoxicity [102].  Therefore, TLHE1 is a very good candidate for conjugation 
to peptides. 
We used trypsin to test the ability of hTTR to protect TLHE1-peptide conjugate 5, from 
proteolysis in buffer.  While there was no protection against proteolysis for Arg-Gly-Lys-MCA 
in the presence of hTTR, there was significant protection against proteolytic hydrolysis for 5 
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when hTTR is present (Figure 3.12).  The protective effect of hTTR was eliminated when the 
reaction mixture was incubated with AG10.  This clearly showed that the protection effect was 
mainly due to binding of 5 to hTTR.  
To test the ability of hTTR to protect peptides against proteolytic hydrolysis in serum, we 
used two peptides, neurotensin (NT; 13 amino-acid neuropeptide) and gonadotropin-releasing 
hormone (GnRH; 10 amino-acid peptide hormone).  NT and GnRH have short in vivo t1/2 (2–6 
min) due to their high renal clearance and proteolytic degradation [108, 109].  The N-terminus of 
NT is amenable for modifications [110] and therefore we conjugated TLHE1, through a short 
linker (~230 Da), to the N-terminus of NT to give 6.  The N- and C-termini of GnRH are 
important for binding to the GnRH receptor (GnRH-R) [111] and only modifications at Gly6 
gives rise to potent analogs.  However, in order for us to investigate the proteolytic protection 
effect of hTTR (i.e. slowing the cleavage of the Gly6 and Leu7 peptide bond) we conjugated 
TLHE1 to the N-terminus of GnRH to give 7.  For control, we synthesized Linker modified NT 
and GnRH (NT—Linker and GnRH—Linker) that does not have TLHE1.  As expected, NT and 
GnRH had the lowest stability in serum (no detectable amounts of NT and GnRH after 4 h and 2 
h, respectively; Figure 3.13).  In comparison, 6 (22 ± 1% remaining at 48 h) and 7 (58 ± 4% 
remaining at 48 h) showed the most protection against serum proteases.  It is important to note 
that while attaching short linker to GnRH resulted in enhancement of protection against 
proteases, and this conjugate is still considered a small molecule (<2 kDa) that would be excreted 
rapidly by kidneys.  Therefore, we predict that recruitment of hTTR played a major effect in 
enhancing the in vivo t1/2 of 6 and 7 (by also decreasing glomerular filtration).  As expected, 
there was no difference in NT—Linker and GnRH—Linker stability between normal serum and 
serum incubated with AG10.  On the other hand, the stability of 6 and 7 in normal serum was 
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higher than that in serum samples pre-incubated with AG10 (no detectable amount of 6 and 7 
after 24 h and 48 h, respectively).  While AG10 decreased conjugates protection by hTTR, we 
did not observe complete blockage of protection.  AG10 binds with 4.8 nM (Kd1) only to the first 
T4 binding site (i.e. 50 % of hTTR or 5 µM).  The binding affinity of AG10 to the second 
binding site (Kd2) (~50 % of hTTR) is 314 nM which is close to the binding affinity of our 
conjugates.  Therefore, we do not expect AG10 to be able to effectively displace all of the 
conjugates from hTTR.  Accordingly, based on our discussion of the Kd values, in addition to 
covalent-probe serum data (Figure 3.9), the majority of conjugates protection would be a result 
of binding to >50 % of hTTR (Table 3.1). 
For testing our hypothesis in vivo, we used GnRH as a model peptide.  GnRH agonists are 
drugs used for treating prostate and breast cancer, as well as fertility disorders [112].  We believe 
that there is likely room for further improvement in t1/2 of GnRH conjugates by improving their 
affinity to hTTR, which could provide the strategy with the potential to be optimized for a 
tunable t1/2 extension of peptides.  We have shown that linking GnRH to TLHE1 (7) protected 
GnRH from proteases in serum (Figure 3.13).  In contrast, GnRH-A has a relatively short in vivo 
t1/2 due to its fast renal excretion (despite its resistance to proteolysis).  Thus, we compared the 
effect of conjugation to TLHE1 on the enhancement of in vivo t1/2 for 7 (short t1/2 due to proteases 
and renal excretion) vs. 8 (short t1/2 mainly due to renal excretion) in rats.  The similarity between 
hTTR and rTTR (83 % sequence identity at the amino acid level) [113] allowed us to evaluate 
the effect of TTR on our peptide conjugates (7 and 8) t1/2  in vivo.  Our in vivo pharmacokinetic 
evaluation of GnRH conjugates (GnRH, GnRH–Linker and 7) in rats showed that there was no 
measurable amount of GnRH at 15 min after administration, which is consistent with the 
reported short in vivo t1/2 (Figure 3.14).  In contrast, 7 displayed initial rapid distribution phase 
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(t1/2 = 12 min) followed by a longer terminal t1/2 (46 ± 3 min).  The terminal t1/2 of 7 is at least 13-
fold longer than that of GnRH or GnRH—Linker (Figure 3.14).  The biphasic profile of 7 was 
similar to what we have observed for AG10 and indicates a TMDD.  There was ~3-fold decrease 
in the t1/2 of 7 in the presence of AG10 (t1/2 = 16 ± 1 min), which is consistent with what we have 
observed in the serum protease experiment (Figure 3.15).  As expected, pharmacokinetic 
evaluation of GnRH-A conjugates (GnRH-A, GnRH-A–Linker and 8) in rats showed that the t1/2 
of GnRH-A was longer (55 ± 11 min) than GnRH, and there was no detectable level in plasma 
after 2 h of administration.  In comparison, 8 displayed initial rapid distribution phase (t1/2 = 14 
min) followed by a much longer terminal t1/2 (180 ± 12 min) which is >3-fold longer than the t1/2 
of GnRH-A.  While there were no detectable plasma levels of GnRH-A after 2 h, 8 was present 
in circulation for at least 12 h (Figure 3.19).  These data strongly support and validate our 
approach that TTR recruitment can indeed enhance the t1/2 of peptides in vivo. 
We also used SPR to evaluate the interaction of 8 with hTTR in the presence of GnRH-R and 
our results showed that conjugate 8 was able to preferentially interact with GnRH-R over hTTR 
(Figure 3.16 and 3.17).  We do not anticipate that a major percentage of 8 could bind to GnRH-R 
and hTTR simultaneously as formation of such a ternary complex would have resulted in large 
increase in SPR response units (µRiU) due to the large size of GnRH-R.  Also, in an effort to 
rule out the possibility that 8 would interfere with the holo-RBP binding to TTR, we studied the 
interaction between holo-RBP-TTR in buffer using SPR.  Our results showed that the SPR 
response from an immobilized TTR on a sensor chip to a mixture of 8 and holo-RBP (74 ± 1 
μRiU) was the sum of their individual responses (34± 0.1 μRiU and 46± 0.1 μRiU, respectively) 
indicating that TTR can indeed interact with both 8 and holo-RBP in concert and is consistent 
with data reported in literature.  
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GnRH agonists interact with GnRH-R in the pituitary gland and are known to cause prompt 
increase in testosterone levels in male rats [107].  Therefore, the in vivo efficacy of 8 on 
circulating levels of testosterone was evaluated in male rats.  The comparable efficacy at 1 h for 
both compounds is consistent with the similar in vitro GnRH-R binding affinity for GnRH-A (Kd 
= 1.8 nM) and 8 (Kd = 4.9 nM).  While testosterone levels in both treated groups started 
decreasing after 1 h, the decline in GnRH-A treated rats was significantly faster than that for 8 
treated rats.  The increase in testosterone levels for rats treated with 8 at 6 h could be due to the 
daily rhythmicity of serum testosterone concentration in male rats [114].  For GnRH-A, the 
circulating testosterone levels returned to vehicle treated levels (3.6 ± 0.6 ng/ml) within 8 h after 
dosing.  In contrast, the testosterone level for rats treated with 8 was still elevated at 12 h post 
dosing (12.7 ± 2.3 ng/ml; increase of ~16 fold above basal levels).  This efficacy data correlates 
well with our pharmacokinetic data (Figure 3.19) and has strongly shown that the enhanced 
efficacy of 8 is a result of extended circulating t1/2, mainly due to its binding to rTTR. 
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Figure 3.12 Structure of hTTR bound to AG10, in silico modeling of linker length. (a) Ribbon 
diagram with transparent surface of hTTR and a close up top view of AG10 (shown as stick) 
bound in one of the two hTTR T4 binding sites (pdb id: 4HIQ). The interaction between AG10 
and the hTTR monomers (expanded box) are highlighted by two H-bonds with Ser117 and 117´ 
and two salt bridges with Lys15 and 15´. Based on this information, no changes were made to 
the pyrazole ring or the carboxyl group of AG10. (b) Structure of AG10 analog 2 with potential 
sites for linker attachment. The position is pointing out towards the solvent and therefore 
attaching a linker will project it outside of the T4 binding pocket without major steric clashes 
with residues at the periphery of the T4 pocket. (c) The distance from the meta-position on the 
phenyl ring carbon of 2 to residues at the outermost of the binding pockets are given. The 
shortest possible distance from the meta-position on 2 to the top of the entrance is about 14.4Å. 
The distance to the ridge of the narrow side of top ellipse is ~17.3Å. This implies that the linker 
should be as long as 17±3Å. (d) The peptide conjugates has a linker length of ~20 Å which 
should be sufficient to clear out of the hTTR T4 binding sites and potentially be functionalized 
with peptides. * Modelling studies were performed by Dr. Jerry Tsai group, Department of 
Chemistry, University of the Pacific, Stockton, California. 
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3.4 Conclusion 
While conjugation to albumin and PEG are attractive technologies for large polypeptides and 
proteins, the TLHE system would complement these technologies by specifically enhancing the 
pharmacokinetic properties of shorter peptides.  Besides maintaining potency, our strategy offers 
a number of advantages over traditional genetic fusion and PEGylation approaches: (i) our 
approach involve a simple chemical conjugation of peptides to TLHE1, and the products are 
homogeneous and can be easily characterized and purified (purity >98 %) using harsh conditions 
such as HPLC.  The modular nature of the synthesis offers flexibility of attachment sites and 
incorporation of unnatural amino acids or non-peptidic functionality into the peptide backbone; 
(ii) Unlike HSA peptide fusions, where the three-dimensional structure of the fusion partner 
needs to be maintained, conjugation to TLHE1 results in stable products that do not require 
refrigeration.  This would decrease the cost of production and storage of peptide conjugates; (iii) 
Because of the smaller size of our conjugates (<3 % the size of HSA conjugates), we anticipate it 
to penetrate solid tumors efficiently; (iv) Due to its non-peptidic nature and small size, it is 
unlikely that TLHE1 can cause immunogenic response; (v) The TLHE system would be 
preferred for certain applications where prolonged exposure to peptides is undesirable. 
Although not explicitly addressed in this report, we envision that our approach could 
potentially be applicable for enhancing in vivo t1/2 of proteins, oligonucleotides, 
oligosaccharides, liposomes, imaging agents, and small molecule drugs.  This should broaden the 
scope and utility of our approach.  In conclusion, we have developed a new approach for 
enhancing the in vivo t1/2 and efficacy of GnRH-A.  Our approach has potential to improve the 
pharmacokinetic properties of other peptides, which would decrease production cost and increase 
their clinical success rate.  
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3.5 Methods 
Materials.  Human hTTR (purified from human plasma) was purchased from Sigma 
(#P1742).  Human serum was purchased from Sigma (#H4522) [hTTR concentration in serum 
was measured using nephelometric analyzer (28 mg/dL or 5 µM)].  HSA was obtained from 
Sigma (#A3782; Albumin from human serum, ≥99 %).  Thyroxine (T4) was purchased from 
Fisher Scientific. AG10, tafamidis, and covalent-probe were synthesized as reported earlier [3, 
57].  All reactions were carried out under argon atmosphere using dry solvents, unless otherwise 
noted.  The solvents used were ACS reagent (anhydrous) grade from Fisher Scientific. Reagents 
were purchased from Aldrich and Acros, and used without further purification.  Reactions were 
monitored by thin-layer chromatography (TLC) carried out on 0.20 mm POLYGRAM® SIL 
silica gel plates (Art.-Nr. 805 023) with fluorescent indicator UV254 using UV light as a 
visualizing agent.  Normal phase flash column chromatography was carried out using Davisil® 
silica gel (100–200 mesh, Fisher Scientific).  1H NMR and 13C NMR spectra were recorded on a 
Jeol JNM−ECA600 spectrometer and High resolution mass spectra (HRMS) were determined by 
JEOL AccuTOF DART using helium as an ionization gas as described in paragraph 2.6. 
Animals.  Adult jugular vein cannulated male Sprague-Dawley rats purchased from Charles 
River Laboratories.  All animals were maintained in a temperature-controlled room (22.2 °C) 
with a photoperiod of 12-h light/12-h dark (lights on at 6:00 AM).  Rat chow (Lab diet™ #5001) 
and tap water were provided ad libitum.  Animal supplies including catheter maintenance 
solutions were purchased from SAI infusion technologies.  Sterile intravenous fluids were 
obtained from Patterson Veterinary.  All animal protocols were approved by the Animal Care 
Committee of the University of the Pacific and complied with the Guide for the Care and Use of 
Laboratory Animals (Eighth Edition, 2011).  
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Chemical synthesis of 2. 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)benzoic acid (2): 
Compound 2 was synthesized starting with 3-hydroxybenzoic acid using a similar approach as 
described for AG10 [3].  Compound 2 is a white solid; 1H NMR (DMSO-d6, 600 MHz): δ 7.51 
(dt, 1H, J = 7.8, 1.2 Hz), 7.42-7.38 (m, 2H), 7.17 (dd, 1H, J = 8.4, 3.0 Hz), 3.92 (t, 2H, J = 6 Hz), 
2.45 (t, 2H, J = 7.2 Hz), 2.04 (s, 6H), 1.85-1.81 (m, 2H); 13C NMR (DMSO-d6, 150 MHz): δ 
10.62, 18.76, 29.62, 66.69, 113.32, 114.68, 119.44, 121.66, 129.95, 132.32, 140.74, 158.79, 
167.27 ppm. HRMS (DART) m/z: calcd for C15H18N2O3 + H+ 275.1396; found 275.1390 (M + 
H+).  
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Figure 3.13 Chemical structure and 1H NMR spectrum for 2. 
  
111 
 
Chemical synthesis of TLHE1.  Methyl 3-hydroxy-5-(pent-4-yn-1-yloxy)benzoate (10): To 
a solution of methyl 3,5-dihydroxybenzoate (9) (0.77 g, 4.58 mmol, 1 equiv) and 4-pentynyl p-
tosylate (0.98 g, 4.12 mmol, 0.9 equiv) in anhydrous MeCN (30 ml) was added K2CO3 (1.267 g, 
9.16 mmol, 2 equiv) and KI (0.153 g, 0.92 mmol, 0.2 equiv, see ).  The suspension was heated to 
reflux for 16 h, filtered, and the solid was rinsed with MeCN.  The filtrate was concentrated 
under reduced pressure.  Water was added to the residue and the aqueous phase was extracted 
with EtOAc, washed brine and dried with Na2SO4.  The solution was filtered and concentrated 
and the residue was purified by flash column chromatography (silica gel, 1-10 % 
EtOAc/hexanes) to afford compound 10 (0.684 g, 71 % yield); 1H NMR (CDCl3, 600 MHz) δ 
7.16-7.14 (m, 2H), 6.62 (t, 1H, J = 2.4 Hz), 4.08 (t, 2H, J = 6.0 Hz), 3.89 (s, 3H), 2.42-2.38 (m, 
2H), 2.02-1.96 (m, 3H); 13C NMR (CDCl3, 150 MHz): δ  15.05, 27.94, 52.47, 66.39, 69.07, 
83.30, 107.22, 107.58, 109.35, 131.64, 157.01, 160.05, 167.46 ppm.  (ESI+) m/z: calcd for 
C13H14O4 + H+ 235.0970; found 235.0961 (M + H+).  
Methyl 3-hydroxy-5-(pent-4-yn-1-yloxy)benzoate (11): To a solution of 10 (360 mg, 1.54 
mmol, 1 equiv) and 1,3-dibromopropane (0.78 ml, 7.7 mmol, 5 equiv) in DMF (5 ml) was added 
K2CO3 (256 mg, 1.85 mmol, 1.2 equiv).  The reaction mixture was stirred at r.t. for 16 hours.  
The mixture was diluted with EtOAc (150 ml), washed with brine (3x50 ml) and dried with 
Na2SO4. The solution was filtered and concentrated.  The residue was purified by flash column 
chromatography (silica gel, 1-10 % EtOAc/hexanes) to afford compound 11 (468 mg, 86 % 
yield); 1H NMR (CDCl3, 600 MHz) δ 7.19-7.17 (m, 2H), 6.64 (t, 1H, J = 2.4 Hz), 4.12 (t, 2H, J = 
5.8 Hz), 4.08 (t, 2H, J = 6.0 Hz), 3.89 (s, 3H), 3.59 (t, 2H, J = 6.4 Hz),  2.42-2.38 (m, 2H), 2.33-
2.29 (m, 2H), 2.02-1.96 (m, 3H); 13C NMR (CDCl3, 150 MHz): δ 15.11, 28.03, 29.81, 32.19, 
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52.23, 65.56, 66.42, 68.99, 83.26, 106.61, 107.77, 107.93, 131.98, 159.64, 159.89, 166.74 ppm. 
(ESI+) m/z: calcd for C16H19BrO4 + H+ 355.0545; found 355.0529 (M + H+).  
Methyl 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-5-(pent-4-yn-1-yloxy)benzoate (12): A 
solution of 11 (450 mg, 1.27 mmol, 1 equiv) in benzene (3 ml) was added dropwise to  a solution 
of acetyl acetone (0.26 ml, 2.54 mmol, 2 equiv) and DBU (0.38 ml, 2.54 mmol, 2 equiv) in 
benzene (7 ml).  The reaction mixture was stirred at r.t. for 3 days.  The mixture was filtered and 
passed through a pad of silica gel.  The solvent were removed and the residue was dissolved in in 
ethanol (5 ml).  Hydrazine hydrate (0.17 ml, 3.18 mmol, 2.5 equiv) was added and the reaction 
was heated under reflux for 4 hours.  The reaction was concentrated and purified by flash column 
chromatography (silica gel, 1-20 % MeOH/CH2Cl2) to afford compound 12 (150 mg, 32 % yield) 
in two steps; 1H NMR (CD3OD, 600 MHz) δ 7.13-7.08 (m, 2H), 6.67 (t, 1H, J = 2.34 Hz), 4.07 
(t, 2H, J = 6.0 Hz), 3.90 (t, 2H, J = 6.0 Hz),  3.86 (s, 3H), 2.56 (t, 2H, J = 7.2 Hz), 2.38-2.34 (m, 
2H), 2.23 (t, 1H, J = 2.6 Hz), 2.11 (s, 6H), 1.97-1.88 (m, 4H); 13C NMR (CD3OD, 150 MHz): δ 
10.54, 15.72, 19.82, 29.35, 30.73, 52.73, 67.68, 67.88, 70.12, 84.01, 107.26, 108.59, 108.83, 
115.27, 133.18, 143.30, 145.88, 161.57, 161.59, 168.28 ppm. HRMS (DART) m/z: calcd for 
C21H26N2O4 + H+ 371.1971; found 371.1968 (M + H+). 
3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-5-(pent-4-yn-1-yloxy)benzoic acid (TLHE1, 
3): To a suspension of 12 (85 mg, 0.23 mmol, 1 equiv) in a mixture of THF (3 ml) and water (3 
ml) was added LiOH.H2O (19 mg, 0.46 mmol, 2 equiv).  The reaction mixture was stirred at r.t. 
for 14 h after which it was cooled to 0 oC and carefully acidified to pH 2-3 with 1N aqueous 
HCl.  The mixture was extracted with EtOAc (3 x 20 ml) and the combined organic extracts were 
dried over anhydrous sodium sulfate and concentrated in vacuo.  The crude product was 
subjected to flash column chromatography (silica gel, 10-50 % MeOH/CH2Cl2) to give of 
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TLHE1(3) (59 mg, 73 % yield) as a white solid; 1H NMR (CD3OD, 600 MHz) δ 7.14-7.10 (m, 
2H), 6.66 (t, 1H, J = 2.4 Hz), 4.07 (t, 2H, J = 6.0 Hz), 3.90 (t, 2H, J = 6.0 Hz), 2.57 (t, 2H, J = 
7.2 Hz), 2.38-2.35 (m, 2H), 2.24 (t, 1H, J = 2.4 Hz), 2.12 (s, 6H), 1.97-1.88 (m, 4H); 57 (t, 2H, J 
= 7.2 Hz), 2.38-2.35 (m, 2H), 2.24 (t, 1H, J = 2.4 Hz), 2.12 (s, 6H), 1.97-1.88 (m, 4H); 13C NMR 
(CD3OD, 150 MHz): δ 10.54, 15.75, 19.83, 29.40, 30.79, 67.63, 67.82, 70.08, 84.04, 106.94, 
108.80, 109.02, 115.25, 134.54, 143.30, 161.48, 161.50, 170.06 ppm. HRMS (DART) m/z: calcd 
for C20H24N2O4 + H+ 357.1814; found 357.1818 (M + H+).  
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Figure 3.14 Synthesis of TLHE1 (3). a) K2CO3, KI, MeCN, reflux, 24 h; b) 1,3-dibromopropane, 
K2CO3, DMF, rt, 16 h; c) i. acetylacetone, DBU, benzene, rt, 3 days; ii. hydrazine hydrate, 
ethanol, 90 oC, 4 h; d) LiOH, THF, water, rt, 14 h. 
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Figure 3.15 Chemical structure and 1H NMR spectrum for TLHE1 (3). 
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Chemical synthesis of neurotensin (NT), 16 and 6.  Synthesis of NT: The NT peptide was 
synthesized employing the standard Fmoc/tBu protocols using solid phase synthesis.  The 
synthesis was carried out on an Fmoc-L-Leu-Wang resin (Chem-Impex #02825, 0.57 mmol/g) 
which was swollen in DMF for about 30 min.  The peptide was built by coupling Fmoc protected 
(L)-amino acid monomers to the resin using DIC and HOBT, in DMF and shaking for 2 h.  
During the entire synthesis, Fmoc group deprotection was carried out using solution of 20% 
piperidine in DMF (2x10 mL) and shaking for 3 min and 30 min, respectively.   After each 
coupling and deprotection reaction, the resin was washed with DMF (3×10 mL) and DCM (3×10 
mL) and shaking each time for 2 min.  The coupling and deprotection reactions were monitored 
by performing the Kaiser test.  Once the NT peptide (13 amino acid) synthesis was completed, it 
was cleaved from the resin and deprotection of side chain groups was performed by treating with 
a cleavage cocktail, containing TFA, phenol, deionized water and TIS (88:5:5:2 ratio).  After 
cleavage, the resulting peptide was precipitated by collecting onto cold ether and washed again 
with ether.  Then, the precipitate was separated by centrifugation, dissolved in water, lyophilized. 
Purification by preparative HPLC gave NT.  
NT: Purified yield = 92 mg, 58%; (97% purity by HPLC): tR (column) (C18) = 21.8 min; tR 
(C4) = 16.3 min; ESI-MS: Exact mass calcd for C78H122N21O20 [M+H]+ m/z 1672.9; [M+2H]2+ 
837.0; [M+3H]3+ 558.3. Found: 1673.2, 837.5, 558.8. 
Synthesis of NT—Linker: The NT peptide used was synthesized in a similar way to what is 
describe above for NT, expect using Glutamic acid instead of Pyroglutamic acid at the N-
terminus.  The azide PEG-linker (16, 141 mg, 0.571 mmol) was activated with HATU (141 mg, 
0.571 mmol), HOBt (77 mg, 0.571 mmol), and DIPEA (126 µL, 0.76 mmol) in DMF (3 ml) 
before adding to the NT—conjugated resin (0.19 mmol).  The reaction mixture was shaken for 
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20 h.  The product was then cleaved from the resin and deprotection of side chain groups was 
performed by treating with a cleavage cocktail, containing TFA, phenol, deionized water and TIS 
(88:5:5:2 ratio).  After cleavage, the resulting peptide was precipitated by collecting onto cold 
ether and washed again with ether.  Then, the precipitate was separated by centrifugation, 
dissolved in water, lyophilized.  Purification by preparative HPLC gave NT—Linker.  
NT—Linker: Purified yield = 170 mg, 47%; (99% purity by HPLC): tR (column) (C18) = 
23.2 min; tR (C4) = 17.7 min; ESI-MS: Exact mass calcd for C87H139N24O25 [M+H]+ m/z 1920.0; 
[M+2H]2+ 960.5; [M+3H]3+ 640.7.  Found: 1920.2, 961.0 and 641.0.  
Synthesis of 6: The click (CuAAC) reaction was carried out by reacting NT—Linker (17.3 
mg, 0.009 mmol) with TLHE1 (10 mg, 0.028 mmol), CuI (8 mg, 0.042 mmol), and sodium 
ascorbate (8.4 mg, 0.042 mmol) DMF/piperidine (4:1) (0.5ml).  The mixture was shaken at room 
temperature for 16 h.  The product (6) was purified by preparative HPLC and analyzed as 
described above for NT—Linker. 
6: Purified yield = 4.5 mg, 22%; (99% purity by HPLC): tR (column) (C18) = 26 min; tR (C4) 
= 18.4 min; ESI-MS: Exact mass calcd for C107H163N26O29 [M+H]+ m/z 2276.2; [M+2H]2+ 
1139.1; [M+3H]3+ 759.7. Found: 1139.7, 760.1. 
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Figure 3.16 Synthesis of neurotensin (NT), NT—Linker, and 6. Reagents and conditions: a) 
Fmoc-Leu-Wang resin; b) Fmoc SPPS (all L-amino acids); c) Linker 16, HATU, HOBt. DIPEA, 
DMF, 24 h; d) TFA, phenol, H2O, and TIS (88:5:5:2 ratio) 3 h; e) TLHE1, CuI. sodium 
ascorbate, DMF/piperidine (4:1), 16 h. *Performed in collaboration with Dr. Sravan Penchala. 
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Figure 3.17 HPLC chromatograms of NT (top), NT-Linker (middle) and 6 (bottom). 
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Chemical synthesis of GnRH, GnRH-Linker and 7.  Synthesis of GnRH: The GnRH was 
synthesized employing the standard Fmoc/tBu protocols using solid phase synthesis.  The 
synthesis was carried out on a Rink amide MBHA resin (Novobiochem #855003, 0.79 mmol/g) 
which was swollen in DMF for about 30 min.  For the resin loading step, the resin (400 mg, 0.28 
mmol) was reacted with Fmoc-Gly-OH (416 mg, 1.4 mmol) in DMF (5 ml) and N,N′-
diisopropylcarbodiimide (DIC) (0.219 ml, 1.4 mmol).  The reaction mixture was shaken for 5 h, 
rt. The peptide was built by coupling Fmoc protected (L)-amino acid monomers to the rink 
amide resin using DIC and HOBT, in DMF and shaking for 2 h.  During the entire synthesis, 
Fmoc group deprotection was carried out using solution of 20 % piperidine in DMF (2x10 ml) 
and shaking for 3 min and 30 min, respectively.   After each coupling and deprotection reaction, 
the resin was washed with DMF (3×10 ml) and DCM (3×10 ml) and shaking each time for 2 
min.  The coupling and deprotection reactions were monitored by performing the Kaiser test.  
Once the GnRH deca-peptide synthesis was completed, it was cleaved from the resin and 
deprotection of side chain groups was performed by treating with a cleavage cocktail, containing 
TFA, phenol, deionized water and TIS (88:5:5:2 ratio).  After cleavage, the resulting peptide was 
precipitated by collecting onto cold ether and washed again with ether.  Then, the precipitate was 
separated by centrifugation, dissolved in water, lyophilized. Purification by preparative HPLC 
gave GnRH.  
GnRH: (98 % purity by HPLC): tR (column) (C18) = 28.3 min; tR (C4) = 20.2 min; ESI-MS: 
Exact mass calcd for C55H75N17O13 [M+H]+ 1182.6; [M+2H]2+ 591.8.  Found: 1182.9, 592.2.  
Synthesis of GnRH—Linker: The GnRH peptide used was synthesized in a similar way to 
what is describe above for GnRH, expect using glutamic acid instead of pyroglutamic acid at the 
N-terminus.  The azide PEG-linker (16, 130 mg, 0.526 mmol) was activated with HATU (130 
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mg, 0.526 mmol), HOBt (71 mg, 0.526 mmol), and DIPEA (116 μl, 0.70 mmol) in DMF (2 ml) 
before adding to the GnRH—conjugated resin (0.175 mmol).  The reaction mixture was shaken 
for 20 h.  The product was then cleaved from the resin and deprotection of side chain groups was 
performed by treating with a cleavage cocktail, containing TFA, phenol, deionized water and TIS 
(88:5:5:2 ratio).  After cleavage, the resulting peptide was precipitated by collecting onto cold 
ether and washed again with ether.  Then, the precipitate was separated by centrifugation, 
dissolved in water, lyophilized.  Purification by preparative HPLC gave GnRH—Linker.  
GnRH—Linker: Purified yield = 77 mg, 31 %; (97 % purity by HPLC): tR (column) (C18) = 
33.8 min; tR (C4) = 26.2 min; ESI-MS: Exact mass calcd for C64H92N20O18 [M+H]+ m/z 1429.6; 
[M+2H]2+ 715.3.  Found: 1429.5, 715.6.  
Synthesis of 7: The click (CuAAC) reaction was carried out by reacting resin bound GnRH—
Linker (0.044 mmol) with TLHE1 (47 mg, 0.13 mmol), CuI (42 mg, 0.22 mmol), and sodium 
ascorbate (43.6 mg, 0.22 mmol) DMF/piperidine (4:1) (0. 5ml).  The mixture was shaken at rt for 
16 h.  The product was then cleaved from the resin and deprotection of side chain groups was 
performed by treating with a cleavage cocktail, containing TFA, phenol, deionized water and TIS 
(88:5:5:2 ratio).  After cleavage, the resulting peptide was precipitated by collecting onto cold 
ether and washed again with ether.  Then, the precipitate was separated by centrifugation, 
dissolved in water, lyophilized.  Purification by preparative HPLC gave 7.  
7: Purified yield = 19.6 mg, 25 %; (95.3 % purity by HPLC): tR (column) (C18) = 35.5 min; 
tR (C4) = 29.3 min; ESI-MS: Exact mass calcd for C84H116N22O22 [M+H]+ m/z 1785.9; [M+2H]2+ 
893.4.  Found: 1786.0, 893.7. 
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Figure 3.18 Synthesis of GnRH—Linker, and 7. Reagents and conditions: a) Rink amide resin, 
DIPEA, DCM, 16 h; b) Fmoc SPPS (all L-amino acids); c) Linker 16, HATU, HOBt. DIPEA, 
DMF, 24 h; d) TLHE1, CuI. sodium ascorbate, DMF/piperidine (4:1), 16 h; e) TFA, phenol, 
H2O, and TIS (88:5:5:2 ratio) 3 h. *Performed in collaboration with Dr. Sravan Penchala. 
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Figure 3.19 HPLC chromatograms of GnRH (top), GnRH-Linker (middle) and 7 (bottom). 
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Analysis of AG10, GnRH, GnRH–Linker, and 7 in rat plasma: The analysis was performed 
on an Agilent 1100 series HPLC system connected to a diode array detector operating between 
the UV ranges of 200 – 400 nm and quantified using Agilent Chemstation software.  The mobile 
phase was composed of solvent A consisting methanol-water (5:95, v/v) containing 0.1 % 
trifluoroacetic acid and solvent B consisting methanol-water (95:5, v/v) containing 0.1 % 
trifluoroacetic acid.  The HPLC program was isocratic at 40 % solvent B for 15 min followed by 
gradient separation increasing linearly from 40 % to 70 % solvent B from 15 to 50 min.  The 
HPLC analysis was performed on a Waters™ XBridge C18 column with L1 packing (4.6 X 150 
mm, 5μm) at ambient temperature upon injection of a small volume of 50 μl of each standard 
and/or sample to obtain the chromatogram. 
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Figure 3.20 HPLC chromatogram of AG10, GnRH, GnRH–Linker, and GnRH-Conjugate (7) in 
rat plasma.  
  
126 
 
 
 
 
 
 
 
 
Figure 3.21 Calibration curves used to quantitate AG10, GnRH, GnRH—Linker, and GnRH-
Conjugate (7) in rat plasma. 
  
127 
 
Dose escalation of AG10 in rats.  Adult male Wistar rats, body weight ranging 160–200 g, 
were used for the study.  Escalating single i.v. doses of 5, 20, and 50 mg/kg of AG10 (sodium 
salt solution in water) were administered to three groups of rats (3 rats per group).  Blood 
samples were collected at 0.08, 2, 4, 8, and 24 hour time intervals.  The plasma samples were 
prepared by centrifugation at 15,000 RPM for 5 min.  The resultant plasma was precipitated 
using 2X solvent B (95:5, methanol-water, 0.1 % TFA).  Samples were centrifuged at 15,000 
RPM for 5 minutes and supernatants were stored at –20 oC until analysis by HPLC. 
Surface Plasmon Resonance (SPR) assay for hTTR-ligands interaction.  All SPR binding 
studies were performed at 25 °C using a SR7000DC Reichert SPR spectrometer, equilibrated 
with 1 % DMSO in phosphate buffered saline (pH 7.4, containing 0.05 % TWEEN® 20, Sigma 
Cat # P3563) as a running buffer.  Preparation of hTTR-Coated Sensor Surfaces; TTR was 
immobilized (1873.732  µRiU, 1 µRiU = 0.73 RU) to a Carboxymethyl Dextran Hydrogel 
Surface Sensor Chip (Reichert Part #13206066)  via an amino-coupling procedure, using running 
buffer and a flow rate of 25 μl/min.  More specifically, the sensor chip was preconditioned with 
three consecutive 1 min injections of running buffer to stabilize baseline.  Then, the surface was 
activated with 0.087 M NHS/0.2 M EDC (25 μl/min for 8 min), and functionalized by injecting a 
solution of hTTR (20 µg/ml, 6 min) in Sodium acetate buffer (pH 4.5).  Finally, unreacted NHS 
esters were deactivated with 1M ethanolamine, pH 8.5 (8 min).  The control flow cell was also 
treated with NHS/EDC followed by ethanolamine.  The experimental data were corrected for 
bulk and instrumental artifacts by double referencing to a control sensor chip surface and blank 
buffer injections.  Test compounds were flowed over the hTTR sensor chip at increasing 
concentrations, and the Kd values were determined. In SPR, the binding of ligands to hTTR is 
measured by resonance units (µRiU) that are proportional to affinity and/or size of any species 
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that interacts with hTTR and changes the refractive index on the chip surface.  The kinetic data 
was fitted to a one-to-one binding model using Scrubber2 software (BioLogic Software v2.0b).  
Evaluating the effect of 8 on holo-RBP—hTTR interaction in buffer.  SPR was used to 
investigate the effect conjugates on holo-RBP—hTTR interaction in buffer.  The conditions and 
buffers used for this assay are similar to what is described above.  Solutions of holo-RBP (0.2 
µM) (Athens Research: #16-16-180216), 8 (4 µM), and a pre-incubated mixture of holo-RBP 
(0.2 µM) and 8 (4 µM) were injected over the hTTR sensor chip and the magnitude of 
interactions (µRiU) were recorded over time. 
Evaluation of the pharmacokinetic profile of 7 and 8 in rats.  Jugular vein cannulated 
Sprague–Dawley male rats (200–220 g, 49–52 days old) were used for this study.  An extension 
catheter was attached to the indwelling jugular vein cannula to facilitate remote sampling.  The 
animals were randomly divided into two groups (N =3 or 4): control group and treatment group.  
The treatment group was pretreated intravenously with AG10 (5.0 mg/kg body weight; 17.1 
µmole/kg; in 200 μl sterile water) followed by a single combined intravenous dose of molar 
equivalent (as a single i.v. dose; 3.3 µmole/kg of each compound) of all test compounds: For 7 
study [GnRH (3.87 mg/kg), GnRH—linker (4.68 mg/kg), 7 (8.83 mg/kg)] and for 8 study 
[GnRH-A (4.1 mg/kg), GnRH-A—linker (4.85 mg/kg), 8 (6.0 mg/kg)] (in 38 % PEG-400, 5 % 
DMSO in saline).  Simultaneously, the control group was pretreated with vehicle (sterile water) 
followed by a single combined intravenous dose of molar equivalent of all test compounds as 
described above.  Blood (0.2 ml) was collected from each rat, via jugular vein cannula, in 
heparinized tubes at each time point (at 0.033, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h) post-dosing and 
the volume replaced with normal saline.  The plasma samples were prepared by centrifugation at 
15,000 RPM for 5 min. The resultant plasma was precipitated using 2X solvent B (95:5, 
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methanol-water, 0.1 % TFA).  Samples were centrifuged at 15,000 RPM for 5 minutes and 
supernatants were analyzed immediately by HPLC.  The peak areas were used to quantitate the 
test compounds based on calibration curve for these compounds in rat plasma.  The identity of 
the peaks for test compounds was also confirmed by LC-MS.  The concentrations in the plasma 
samples were then plotted as their natural logarithms against time.  A two-compartment model 
(using WinNonlin®) was used to obtain all the pharmacokinetic parameters. 
Evaluation of the efficacy of 8 in rats. Jugular vein cannulated Sprague–Dawley male rats 
(300–325 g, 68–73 days old) were used for this study.  An extension catheter was attached to the 
indwelling jugular vein cannula to facilitate remote sampling.  To optimize experimental 
conditions and to minimize stress, animals were allowed to acclimate to the procedure room and 
the procedure room was kept quiet throughout the study.  The animals were randomly divided in 
three groups (N = 4 in each group).  Basal blood samples were withdrawn from all animals ~ 
7:00 AM, considering the circadian rhythm of testosterone.  Group one (N = 4) was a control 
group treated only vehicle (200 μl of 30 % PEG in saline; i.v.); Group two (N = 4) was treated 
with GnRH-A (150 ng/kg, 120 picomoles/kg); Group three (N = 4) was treated with equivalent 
dose of 8 (225 ng/kg, 120 picomoles/kg; i.v.).  The GnRH-A and 8 samples were also prepared 
in the same vehicle as the control (i.e. 200 μl of 30 % PEG-400 in saline).  Blood samples (0.1 
ml) were collected, via jugular vein cannula, for each rat at each time point and the volume was 
replaced with normal saline.  The blood samples were left to clot at r.t. for 30 min, and 
centrifuged at 15000g for 8 min.  The resulting serum was collected and stored in a –20 °C 
freezer until assayed for testosterone. 
Serum testosterone levels were measured using an established rat ELISA assay (ALPCO 
Diagnostics, cat # 55-TESMS-E01).  The testosterone ELISA assay is a competitive 
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immunoassay for the quantitative measurement of testosterone in rat serum.  The assay was 
performed according to the kit manufacturer’s protocol.  Known concentrations of testosterone 
were used to generate a standard curve.  The sensitivity of the kit was 0.066 ng/ml.  Testosterone 
levels were expressed as mean ± SEM.  
Statistical analyses.  Unless stated otherwise, all statistical analyses were performed using 
GraphPad Prism and the results of all in vitro and in vivo experiments are presented as either 
means ± SEMor ± S.D of at least 3–4 replicates per group per study.  The analysis of the results 
obtained in the evaluation of in vivo compound 8 efficacy experiments was performed using one-
way ANOVA followed by post hoc Dunnett’s multiple comparisons test at each particular time 
point.  P values lower than 0.05 were considered significant. 
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Chapter 4: Development of a Probe for the Quantitation of TTR in Human Serum 
4.1 Introduction 
Quantification of serum proteins has long been established as an effective measure of various 
aspects of human health.  Healthy levels (specified usually weight by volume; e.g. mg/L) of 
many proteins have been set and having too much or too little (usually a deficit) can lead to 
multiple disease states.  Typically, human serum albumin (HSA) is quantified in normal, healthy 
patients as an indicator of nutritional status.  However, due to the biological t1/2 of HSA being 
~20 days, testing HSA for nutritional status isn’t sensitive.  Due to this, transthyretin may be 
used as a nutritional marker substitute for critical patients, such as patients who have recently 
undergone major surgery and require more precise monitoring of their nutritional status as an 
indicator of their recovery.  
Current clinical assays for quantifying TTR tetramers in serum, such as 
immunoprecipitation-turbidity assays, have significant drawbacks.  The cost in materials and 
time make the development of an assay that can accurately measure tetrameric TTR with a 
significant reduction in cost desirable.  The focus of this project is to develop a fluorescence 
polarization assay using an AG10 analogue (similar to TLHE from chapter 3) to bind and give a 
signal representative of the amount of TTR in the sample, after calibration.  Fluorescence 
polarization measures parallel and perpendicular with respect to the plane of linearly polarized 
excitation light emitted.  In solution, molecules freely rotate at a constant rate until they bind to 
another larger molecule.  This phenomenon will be utilized for our AG10 analogue conjugated 
with a fluorescent dye binding to TTR and giving a variation in signal.  
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4.2 Results 
Synthesis and analysis of the first-generation probe, TTRQ1.  Using TLHE1 mentioned in 
the previous section, we conducted multiple linker SAR studies using ‘click-chemistry’.  A short 
(5-C) amine linker showed the best binding to TTR and was selected to move forward. TTRQ1 
in shown in Figure 4.1.  Initially, FITC was selected to conjugate with the TTR-binder to form 
the fluorescent conjugate due to its low cost and wide availability. 
Clinical samples are normally tested as serum; if this assay is to be adopted for use in clinical 
laboratories, it should be optimized to utilize a biological sample such as serum.  Serum contains 
more than 4,000 proteins with widely ranging concentrations.  A probe designed to quantify TTR 
should bind specifically to TTR and preclude the binding of other proteins.  Due to the fact that 
FITC is known to non-specifically bind to serum proteins, such as human serum albumin, to 
assay the specifically of TTRQ1, in addition to the FPE assay, IP-chromatography was 
performed (Figure 4.2).  
Using whole serum and depleted serum obtained from the IP-chromatography, FP assay was 
performed (Figure 4.3).  The results indicate that the addition of the FITC dye to the TTR 
binding domain significantly weakened the binding affinity and specificity of the molecule as a 
conjugate.  
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Figure 4.1 Structure of TTRQ1.  The functional pieces of the conjugate are highlighted: TLHE1, 
the same TTR binding ligand used for half-life extension, a short hydrocarbon linker created 
using click-chemistry, and a FITC fluorescent dye. 
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Figure 4.2 Western Blot analysis of (a) serum before co-immunoprecipitation chromatography, 
(b) serum after co-IP, and (c) the eluted TTR fraction after co-IP. 
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Figure 4.3 Fluorescence Polarization results from a serial dilution of TTRQ1 with normal human 
serum (red) and depleted human serum (blue).  IC50 values: 25 nM TTRQ1+whole serum vs. 80 
nM in depleted serum, loss of roughly 3x binding. 
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Synthesis and analysis of the first-generation probe, TTRQ2.  To determine the specific 
causes of loss of activity, two approaches were undertaken: Further linker studies using FITC as 
the fluorescent dye and consequently the replacement of FITC with a less non-specific binding 
dye with the linker system that produced the best results from the FP assay (such as Cy3B). 
TTRQ2 is shown in Figure 4.4.  We then conducted the initial FPE to discover if the longer 
linker would show any positive impact on any possible steric hindrance effect the molecule may 
have (Figure 4.5).  We concluded that linker may not be the cause of the low binding activity and 
desired to move forward with a new dye (Cy3B), while including the short and long linker 
systems we previously development.  
At this point, the project was halted in order to focus on other more urgent projects (previous 
sections). 
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Figure 4.4 Structure of TTRQ2. The functional pieces of the conjugate are highlighted: TLHE1, 
the same TTR binding ligand used for half-life extension, a longer hydrocarbon/amide linker 
created using click-chemistry, and a FITC fluorescent dye. 
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Figure 4.5 FPE assay analysis of TTRQ1 & TTRQ2 in human serum vs. AG10, Tafamidis, and 
AG10-linker (TTRQ0). 
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4.3 Discussion/Conclusion 
This project was never completed, but the idea of a simple, quick, and low cost assay for the 
quantification of transthyretin would be a considerable advancement over the current method.  
Indeed, if specific binding molecules for any serum protein are available or can be development 
at low cost, then this method can potentially be used for the quantification of that protein by 
fluorescence polarization.  However, from the initial studies that are covered in this section, it is 
clear that the development of a fluorescent probe to be used to quantify TTR in serum by FP is a 
distant realization.  A better binding TTR ligand w/linker is needed and the optimal dye remains 
to be studied.  
4.4 Methods 
FP, FPE, and western blot assay protocols followed are listed previously in this document.  
Synthesis of TTRQ1.  TLHE1-benzoate (47 mg, 0.13 mmol), CuI (42 mg, 0.22 mmol), and 
sodium ascorbate (43.6 mg, 0.22 mmol) were reacted with azide/t-boc-linker (68 mg, .26 mmol) 
in H2O/THF (1:4, 5 mL total).  The reaction mixture was heated under reflux in nitrogen 
atmosphere at 50°C for 24 hours.  The crude reaction mixture was purified by flash 
chromatography (Hex:EtOAc, 60:40) and dried to yield 1 (40 mg). 1 (40 mg, .15 mmol) was 
hydrolyzed using LiOH (25 mg, .30 mmol) in H2O/THF (1:4, 5 mL total) at RT overnight.  The 
reaction mixture was purified by flash chromatography (Hex:EtOAc, 40:60) and dried to yield 2 
(38 mg). tert-boc protecting group on 2 was then removed using 20% TFA in DCM for 4 hours 
at RT to yield TTRQ0 (30 mg); the product was flushed through a hexane column to remove 
most of the TFA and dried for the next reaction.  TTRQ0 (30 mg, .08 mmol) was reacted with 
FITC (10 mg, .03 mmol) with trimethylamine (25 uL, .17 mmol) in DMF (3 mL).  The final 
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product was purified by flash chromatography (Hex/EtOAc, 20:80) to yield TTRQ1 (10 mg, .01 
mmol). 
Synthesis of TTRQ2.  TTRQ0 (10 mg, .02 mmol) was reacted with FITC-linker (5 mg, .02 
mmol) with trimethylamine (15 uL, .12 mmol) in DMF (3 mL).  The final product was purified 
by flash chromatography (Hex/EtOAc, 20:80) to yield TTRQ2 (5 mg, .01 mmol). 
Immunoprecipitation chromatography.  Co-IP was performed with Pierce Co-
Immunoprecipitation Kit (ThermoFisher, cat #: 26149) as per kit instructions with anti-TTR 
antibody obtained from DAKO (Agilent, cat #: A20002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
141 
 
References 
 
1. Monaco, H.L., M. Rizzi, and A. Coda, Structure of a complex of two plasma proteins: 
transthyretin and retinol-binding protein. Science, 1995. 268(5213): p. 1039-41. 
2. Blake, C.C., et al., Structure of prealbumin: secondary, tertiary and quaternary 
interactions determined by Fourier refinement at 1.8 A. J Mol Biol, 1978. 121(3): p. 339-
56. 
3. Penchala, S.C., et al., AG10 inhibits amyloidogenesis and cellular toxicity of the familial 
amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A, 
2013. 110(24): p. 9992-7. 
4. Vivian Cody, A.W., Mechanisms of Molecular Recognition:Structural Characteristics of 
Transthyretin Ligand Interactions. Recent Advances in Transthyretin Evolution, 
Structure and Biological Functions. 2009: Springer‐Verlag Berlin Heidelberg. 
5. Stabilini, R., et al., Influence of age and sex on prealbumin levels. Clin Chim Acta, 1968. 
20(2): p. 358-9. 
6. Devoto, G., et al., Prealbumin serum concentrations as a useful tool in the assessment of 
malnutrition in hospitalized patients. Clin Chem, 2006. 52(12): p. 2281-5. 
7. Kanda, Y., et al., The amino acid sequence of human plasma prealbumin. J Biol Chem, 
1974. 249(21): p. 6796-805. 
8. Foss, T.R., R.L. Wiseman, and J.W. Kelly, The pathway by which the tetrameric protein 
transthyretin dissociates. Biochemistry, 2005. 44(47): p. 15525-33. 
9. Cheng, S.Y., et al., Analysis of thyroid hormone binding to human serum prealbumin by 
8-anilinonaphthalene-1-sulfonate fluorescence. Biochemistry, 1977. 16(16): p. 3707-13. 
10. Neumann, P., V. Cody, and A. Wojtczak, Structural basis of negative cooperativity in 
transthyretin. Acta Biochim Pol, 2001. 48(4): p. 867-75. 
11. Cody, V., Mechanisms of molecular recognition: crystal structure analysis of human and 
rat transthyretin inhibitor complexes. Clin Chem Lab Med, 2002. 40(12): p. 1237-43. 
12. Lundberg, E., Transthyretin and the transthyretin-related protein: A structural study, in 
Umeå Center for Molecular Pathogenesis. 2006, Umeå University: SE-901 87 Umeå, 
Sweden. 
13. Wojtczak, A., et al., Structures of human transthyretin complexed with thyroxine at 2.0 A 
resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. Acta Crystallogr D 
Biol Crystallogr, 1996. 52(Pt 4): p. 758-65. 
14. Liz, M.A., et al., Aboard transthyretin: From transport to cleavage. IUBMB Life, 2010. 
62(6): p. 429-35. 
15. Bartalena, L., Recent achievements in studies on thyroid hormone-binding proteins. 
Endocr Rev, 1990. 11(1): p. 47-64. 
16. Purkey, H.E., M.I. Dorrell, and J.W. Kelly, Evaluating the binding selectivity of 
transthyretin amyloid fibril inhibitors in blood plasma. Proc Natl Acad Sci U S A, 2001. 
98(10): p. 5566-71. 
17. Ferguson, R.N., et al., Negative cooperativity in the binding of thyroxine to human serum 
prealbumin. Preparation of tritium-labeled 8-anilino-1-naphthalenesulfonic acid. 
Biochemistry, 1975. 14(2): p. 282-9. 
18. Goodman, D.S., Vitamin A and retinoids in health and disease. N Engl J Med, 1984. 
310(16): p. 1023-31. 
19. Wolf, G., Multiple functions of vitamin A. Physiol Rev, 1984. 64(3): p. 873-937. 
142 
 
20. Noy, N., E. Slosberg, and S. Scarlata, Interactions of retinol with binding proteins: 
studies with retinol-binding protein and with transthyretin. Biochemistry, 1992. 31(45): 
p. 11118-24. 
21. Naylor, H.M. and M.E. Newcomer, The structure of human retinol-binding protein 
(RBP) with its carrier protein transthyretin reveals an interaction with the carboxy 
terminus of RBP. Biochemistry, 1999. 38(9): p. 2647-53. 
22. Costa, R., et al., Transthyretin binding to A-Beta peptide--impact on A-Beta 
fibrillogenesis and toxicity. FEBS Lett, 2008. 582(6): p. 936-42. 
23. Liz, M.A., et al., Substrate specificity of transthyretin: identification of natural substrates 
in the nervous system. Biochem J, 2009. 419(2): p. 467-74. 
24. Selkoe, D.J., Folding proteins in fatal ways. Nature, 2003. 426(6968): p. 900-4. 
25. Chiti, F. and C.M. Dobson, Protein misfolding, functional amyloid, and human disease. 
Annu Rev Biochem, 2006. 75: p. 333-66. 
26. Sipe, J.D., et al., Amyloid fibril protein nomenclature: 2010 recommendations from the 
nomenclature committee of the International Society of Amyloidosis. Amyloid, 2010. 
17(3-4): p. 101-4. 
27. Foss, T.R., R.L. Wiseman, and J.W. Kelly, The pathway by which the tetrameric protein 
transthyretin dissociates. Biochemistry, 2005. 44(47): p. 15525-33. 
28. Johnson, S.M., et al., Native state kinetic stabilization as a strategy to ameliorate protein 
misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res, 2005. 
38(12): p. 911-21. 
29. Hammarström, P., et al., Prevention of transthyretin amyloid disease by changing protein 
misfolding energetics. Science, 2003. 299(5607): p. 713-6. 
30. Saraiva, M.J., Transthyretin mutations in health and disease. Hum Mutat, 1995. 5(3): p. 
191-6. 
31. Connors, L.H., et al., Tabulation of human transthyretin (TTR) variants, 2003. Amyloid, 
2003. 10(3): p. 160-84. 
32. Sekijima, Y., et al., The biological and chemical basis for tissue-selective amyloid 
disease. Cell, 2005. 121(1): p. 73-85. 
33. Ando, Y. and O.B. Suhr, Autonomic dysfunction in familial amyloidotic polyneuropathy 
(FAP). Amyloid, 1998. 5(4): p. 288-300. 
34. Benson, M.D., Familial amyloidotic polyneuropathy. Trends Neurosci, 1989. 12(3): p. 
88-92. 
35. Jacobson, D.R., et al., Variant-sequence transthyretin (isoleucine 122) in late-onset 
cardiac amyloidosis in black Americans. N Engl J Med, 1997. 336(7): p. 466-73. 
36. Connors, L.H., et al., Cardiac amyloidosis in African Americans: comparison of clinical 
and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light 
chain amyloidosis. Am Heart J, 2009. 158(4): p. 607-14. 
37. Buxbaum, J., et al., Significance of the amyloidogenic transthyretin Val 122 Ile allele in 
African Americans in the Arteriosclerosis Risk in Communities (ARIC) and 
Cardiovascular Health (CHS) Studies. Am Heart J, 2010. 159(5): p. 864-70. 
38. Coelho, T., Familial amyloid polyneuropathy: new developments in genetics and 
treatment. Curr Opin Neurol, 1996. 9(5): p. 355-9. 
39. Hammarström, P., et al., Sequence-dependent denaturation energetics: A major 
determinant in amyloid disease diversity. Proc Natl Acad Sci U S A, 2002. 99 Suppl 4: p. 
16427-32. 
143 
 
40. Jiang, X., J.N. Buxbaum, and J.W. Kelly, The V122I cardiomyopathy variant of 
transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in 
accelerated amyloidosis. Proc Natl Acad Sci U S A, 2001. 98(26): p. 14943-8. 
41. Ruberg, F.L. and J.L. Berk, Transthyretin (TTR) cardiac amyloidosis. Circulation, 2012. 
126(10): p. 1286-300. 
42. Wallace, J.L., Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best 
Pract Res Clin Gastroenterol, 2001. 15(5): p. 691-703. 
43. Westermark, P., et al., Fibril in senile systemic amyloidosis is derived from normal 
transthyretin. Proc Natl Acad Sci U S A, 1990. 87(7): p. 2843-5. 
44. Rapezzi, C., et al., Transthyretin-related amyloidoses and the heart: a clinical overview. 
Nat Rev Cardiol, 2010. 7(7): p. 398-408. 
45. Niemietz, C., G. Chandhok, and H. Schmidt, Therapeutic Oligonucleotides Targeting 
Liver Disease: TTR Amyloidosis. Molecules, 2015. 20(10): p. 17944-75. 
46. Suhr, O.B., et al., Efficacy and safety of patisiran for familial amyloidotic 
polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis, 2015. 10: p. 109. 
47. Hammarström, P., F. Schneider, and J.W. Kelly, Trans-suppression of misfolding in an 
amyloid disease. Science, 2001. 293(5539): p. 2459-62. 
48. Coelho, T., et al., Tafamidis for transthyretin familial amyloid polyneuropathy: a 
randomized, controlled trial. Neurology, 2012. 79(8): p. 785-92. 
49. Sekijima, Y., M.A. Dendle, and J.W. Kelly, Orally administered diflunisal stabilizes 
transthyretin against dissociation required for amyloidogenesis. Amyloid, 2006. 13(4): p. 
236-49. 
50. Berk, J.L., et al., Repurposing diflunisal for familial amyloid polyneuropathy: a 
randomized clinical trial. JAMA, 2013. 310(24): p. 2658-67. 
51. Page, J. and D. Henry, Consumption of NSAIDs and the development of congestive heart 
failure in elderly patients: an underrecognized public health problem. Arch Intern Med, 
2000. 160(6): p. 777-84. 
52. Sant'Anna, R., et al., Repositioning tolcapone as a potent inhibitor of transthyretin 
amyloidogenesis and associated cellular toxicity. Nat Commun, 2016. 7: p. 10787. 
53. Assal, F., et al., Tolcapone and fulminant hepatitis. Lancet, 1998. 352(9132): p. 958. 
54. Jonsén, E., et al., Early liver transplantation is essential for familial amyloidotic 
polyneuropathy patients' quality of life. Amyloid, 2001. 8(1): p. 52-7. 
55. Hamour, I.M., et al., Heart transplantation for homozygous familial transthyretin (TTR) 
V122I cardiac amyloidosis. Am J Transplant, 2008. 8(5): p. 1056-9. 
56. Alhamadsheh, M.M., et al., Potent kinetic stabilizers that prevent transthyretin-mediated 
cardiomyocyte proteotoxicity. Sci Transl Med, 2011. 3(97): p. 97ra81. 
57. Choi, S. and J.W. Kelly, A competition assay to identify amyloidogenesis inhibitors by 
monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to 
transthyretin. Bioorg Med Chem, 2011. 19(4): p. 1505-14. 
58. Siddiqi, O.K. and F.L. Ruberg, Cardiac amyloidosis: An update on pathophysiology, 
diagnosis, and treatment. Trends Cardiovasc Med, 2017. 
59. Tojo, K., et al., Diflunisal stabilizes familial amyloid polyneuropathy-associated 
transthyretin variant tetramers in serum against dissociation required for 
amyloidogenesis. Neurosci Res, 2006. 56(4): p. 441-9. 
60. Arrar, M., C.A. de Oliveira, and J.A. McCammon, Inactivating mutation in histone 
deacetylase 3 stabilizes its active conformation. Protein Sci, 2013. 22(10): p. 1306-12. 
144 
 
61. Adamski-Werner, S.L., et al., Diflunisal analogues stabilize the native state of 
transthyretin. Potent inhibition of amyloidogenesis. J Med Chem, 2004. 47(2): p. 355-74. 
62. Sebastião, M.P., et al., Transthyretin stability as a key factor in amyloidogenesis: X-ray 
analysis at atomic resolution. J Mol Biol, 2001. 306(4): p. 733-44. 
63. Kim, J.H., J. Oroz, and M. Zweckstetter, Structure of Monomeric Transthyretin Carrying 
the Clinically Important T119M Mutation. Angew Chem Int Ed Engl, 2016. 55(52): p. 
16168-16171. 
64. Neto-Silva, R.M., et al., X-ray crystallographic studies of two transthyretin variants: 
further insights into amyloidogenesis. Acta Crystallogr D Biol Crystallogr, 2005. 61(Pt 
3): p. 333-9. 
65. Lima, L.M., et al., Identification of a novel ligand binding motif in the transthyretin 
channel. Bioorg Med Chem, 2010. 18(1): p. 100-10. 
66. Bulawa, C.E., et al., Tafamidis, a potent and selective transthyretin kinetic stabilizer that 
inhibits the amyloid cascade. Proc Natl Acad Sci U S A, 2012. 109(24): p. 9629-34. 
67. Hao, M.H., Theoretical Calculation of Hydrogen-Bonding Strength for Drug Molecules. 
J Chem Theory Comput, 2006. 2(3): p. 863-72. 
68. Choi, S., et al., Chemoselective small molecules that covalently modify one lysine in a 
non-enzyme protein in plasma. Nat Chem Biol, 2010. 6(2): p. 133-9. 
69. Iakovleva, I., et al., Enthalpic Forces Correlate with the Selectivity of Transthyretin-
Stabilizing Ligands in Human Plasma. J Med Chem, 2015. 58(16): p. 6507-15. 
70. Yi, S., et al., Systemic amyloidosis in transgenic mice carrying the human mutant 
transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic 
polyneuropathy, type I. Am J Pathol, 1991. 138(2): p. 403-12. 
71. Kohno, K., et al., Analysis of amyloid deposition in a transgenic mouse model of 
homozygous familial amyloidotic polyneuropathy. Am J Pathol, 1997. 150(4): p. 1497-
508. 
72. Fex, G., C.B. Laurell, and E. Thulin, Purification of prealbumin from human and canine 
serum using a two-step affinity chromatographic procedure. Eur J Biochem, 1977. 75(1): 
p. 181-6. 
73. Coelho, et al., Compound heterozygotes of transthyretin Met30 and transthyretin Met119 
are protected from the devastating effects of familial amyloid polyneuropathy. 
Neuromuscul Disord, 1996. 6: p. S20. 
74. Bartels, T., J.G. Choi, and D.J. Selkoe, α-Synuclein occurs physiologically as a helically 
folded tetramer that resists aggregation. Nature, 2011. 477(7362): p. 107-10. 
75. Alhamadsheh, M.M., et al., Potent kinetic stabilizers that prevent transthyretin-mediated 
cardiomyocyte proteotoxicity. Sci Transl Med, 2011. 3(97): p. 97ra81. 
76. Berman, H.M., et al., The Protein Data Bank. Nucleic Acids Res, 2000. 28(1): p. 235-42. 
77. Pettersen, E.F., et al., UCSF Chimera--a visualization system for exploratory research 
and analysis. J Comput Chem, 2004. 25(13): p. 1605-12. 
78. Schaftenaar, G. and J.H. Noordik, Molden: a pre- and post-processing program for 
molecular and electronic structures. J Comput Aided Mol Des, 2000. 14(2): p. 123-34. 
79. Becke, A. Density‐functional thermochemistry. III. The role of exact exchange. 1993. 
98, 5648-5652       
80. McLean, A. and G. Chandler Contracted Gaussian basis sets for molecular calculations. 
I.Second row atoms, Z= 11–18. The Journal of Chemical Physics 1980. 72, 5639-5648. 
81. MJ, F., et al. Gaussian 09. Wallingford, CT, USA: Gaussian, Inc., 2009. 
145 
 
82. Lang, P.T., et al., DOCK 6: combining techniques to model RNA-small molecule 
complexes. RNA, 2009. 15(6): p. 1219-30. 
83. Boohaker, R.J., et al., The use of therapeutic peptides to target and to kill cancer cells. 
Curr Med Chem, 2012. 19(22): p. 3794-804. 
84. Kaspar, A.A. and J.M. Reichert, Future directions for peptide therapeutics development. 
Drug Discov Today, 2013. 18(17-18): p. 807-17. 
85. Tweedle, M.F., Peptide-targeted diagnostics and radiotherapeutics. Acc Chem Res, 
2009. 42(7): p. 958-68. 
86. Morgat, C., et al., Targeting neuropeptide receptors for cancer imaging and therapy: 
perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med, 
2014. 55(10): p. 1650-7. 
87. Kontermann, R., Therapeutic Proteins: Strategies to Modulate Their Plasma Half-lives. 
Weinheim: Wiley-VCH Verlag GmbH & Co. 2012. 
88. Gaberc-Porekar, V., et al., Obstacles and pitfalls in the PEGylation of therapeutic 
proteins. Curr Opin Drug Discov Devel, 2008. 11(2): p. 242-50. 
89. Bendele, A., et al., Short communication: renal tubular vacuolation in animals treated 
with polyethylene-glycol-conjugated proteins. Toxicol Sci, 1998. 42(2): p. 152-7. 
90. Schellenberger, V., et al., A recombinant polypeptide extends the in vivo half-life of 
peptides and proteins in a tunable manner. Nat Biotechnol, 2009. 27(12): p. 1186-90. 
91. Mitragotri, S., P.A. Burke, and R. Langer, Overcoming the challenges in administering 
biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov, 2014. 
13(9): p. 655-72. 
92. Alconcel, S.N., A.S. Baas, and H.D. Maynard, FDA-approved poly(ethylene glycol)–
protein conjugate drugs. Polymer Chemistry, 2011. 2: p. 1442–1448. 
93. Hopp, J., et al., The effects of affinity and valency of an albumin-binding domain (ABD) 
on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel, 2010. 
23(11): p. 827-34. 
94. Levy, O.E., et al., Novel exenatide analogs with peptidic albumin binding domains: 
potent anti-diabetic agents with extended duration of action. PLoS One, 2014. 9(2): p. 
e87704. 
95. Dennis, M.S., et al., Albumin binding as a general strategy for improving the 
pharmacokinetics of proteins. J Biol Chem, 2002. 277(38): p. 35035-43. 
96. Zobel, K., et al., Phosphate ester serum albumin affinity tags greatly improve peptide 
half-life in vivo. Bioorg Med Chem Lett, 2003. 13(9): p. 1513-5. 
97. Trüssel, S., et al., New strategy for the extension of the serum half-life of antibody 
fragments. Bioconjug Chem, 2009. 20(12): p. 2286-92. 
98. Ahlskog, J.K., et al., In vivo targeting of tumor-associated carbonic anhydrases using 
acetazolamide derivatives. Bioorg Med Chem Lett, 2009. 19(16): p. 4851-6. 
99. Lubberink, M., et al., 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine 
tumors with PET. J Nucl Med, 2002. 43(10): p. 1391-7. 
100. Engstrøm, T., et al., Oxytocin receptor binding and uterotonic activity of carbetocin and 
its metabolites following enzymatic degradation. Eur J Pharmacol, 1998. 355(2-3): p. 
203-10. 
101. Ingenbleek, Y. and V. Young, Transthyretin (prealbumin) in health and disease: 
nutritional implications. Annu Rev Nutr, 1994. 14: p. 495-533. 
146 
 
102. Penchala, S.C., et al., A biomimetic approach for enhancing the in vivo half-life of 
peptides. Nat Chem Biol, 2015. 11(10): p. 793-8. 
103. Mager, D.E. and W.J. Jusko, General pharmacokinetic model for drugs exhibiting target-
mediated drug disposition. J Pharmacokinet Pharmacodyn, 2001. 28(6): p. 507-32. 
104. Wegener, D., et al., A fluorogenic histone deacetylase assay well suited for high-
throughput activity screening. Chem Biol, 2003. 10(1): p. 61-8. 
105. Nagy, A. and A.V. Schally, Targeting of cytotoxic luteinizing hormone-releasing 
hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod, 
2005. 73(5): p. 851-9. 
106. Halmos, G., et al., Down-regulation of pituitary receptors for luteinizing hormone-
releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci 
U S A, 1996. 93(6): p. 2398-402. 
107. Anderes, K.L., et al., Biological characterization of a novel, orally active small molecule 
gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J 
Pharmacol Exp Ther, 2003. 305(2): p. 688-95. 
108. Seminara, S.B., F.J. Hayes, and W.F. Crowley, Gonadotropin-releasing hormone 
deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's 
syndrome): pathophysiological and genetic considerations. Endocr Rev, 1998. 19(5): p. 
521-39. 
109. Barelli, H., et al., Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in 
vivo, in the vascularly perfused dog ileum. Br J Pharmacol, 1994. 112(1): p. 127-32. 
110. Morgat, C., et al., Targeting neuropeptide receptors for cancer imaging and therapy: 
perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med, 
2014. 55(10): p. 1650-7. 
111. Hayden, C., GnRH analogues: applications in assisted reproductive techniques. Eur J 
Endocrinol, 2008. 159 Suppl 1: p. S17-25. 
112. Vickery, B.H., Comparison of the potential for therapeutic utilities with gonadotropin-
releasing hormone agonists and antagonists. Endocr Rev, 1986. 7(1): p. 115-24. 
113. Sundelin, J., et al., The primary structure of rabbit and rat prealbumin and a comparison 
with the tertiary structure of human prealbumin. J Biol Chem, 1985. 260(10): p. 6481-7. 
114. Mock, E.J., H.W. Norton, and A.I. Frankel, Daily rhythmicity of serum testosterone 
concentration in the male laboratory rat. Endocrinology, 1978. 103(4): p. 1111-21. 
 
 
